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ABSTRACT 
 
Exploring the Impact of Hemodynamic and Hemorheology in the Design of Carrier for 
Vascular-Targeted Drug Delivery in Atherosclerosis   
by 
Katawut Namdee 
 
Chair: Omolola Eniola-Adefeso 
 
Recently, targeting drug carriers (VTCs) have become one of the most 
distinguished aspects in the field of pharmaceutical engineering. In order to sustain the 
ability of localized drug release over time, a carrier must survive through the circulatory 
system, travel to and be retained at a specific site. Therefore, a multitude of strategies have 
to be considered and implemented to achieve an optimal performing VTC design. Herein, 
the presented studies aim to elucidate the coupled effect of VTC physical and material 
properties and the characteristics in prescribing the efficiency of VTCs to localize and bind 
xxi 
 
to the vascular wall in atherosclerosis via in vitro flow assays and a mouse model 
atherosclerosis.  
In the first study, we explore the impact of VTC shapes on their functionality in 
targeting atherosclerosis and found that targeted microrods were more effective at adhering 
to mouse aortas than micro and nanospheres, while nanorodsparticles displayed the same 
minimal adhesion levels as nanospheres due to poor localization to the vessel wall. We also 
found that targeted microparticles were retained at high levels in the lungs, likely due to 
molecular interaction with the pulmonary endothelium.   
In the second study, we explore how particle size, along with hemodynamics (blood 
shear rate and vessel size) and hemorheology (blood hematocrit) affect the adhesion of 
VTCs in a microfluidic assays. Microspheres also were found to exhibit disproportionately 
higher vascular wall adhesion than nanospheres in all hemodynamic conditions, due to the 
higher ability to localize to the wall.  
Moreover, we also investigate the role of hemorheology (RBC’s dimension) on 
dictating the binding efficiency of spherical VTCs. Our results suggest that the ratio of 
RBCs size to the carrier size dictate the particle binding.  
Finally, we study the potential role of plasma proteins and material types which 
affect the adhesion efficiency of VTCs under the blood flow assays. The results show that 
the plasma proteins in different species have different effects on particle binding, especially 
porcine, which show strong negative effect on particle adhesion. This study offers the first 
evaluation of plasma proteins in different animal species to determine how they affect 
VTCs.    
xxii 
 
In conclusion, we address the crucial factors of hemodynamics, hemorheology and 
plasma protein to VTC design. This important for many research fields, particularly for the 
design of drug delivery and diagnostics in cardiovascular diseases as these parameters can 
be used to improve carrier performance. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Background and significance 
In recent decades, drug delivery systems have become one of the most distinguished 
aspects of the field of biomedical and pharmaceutical engineering, especially the targeting of 
carriers for delivery of therapeutics in human diseases via the vascular system.  Drug delivery 
systems enhance drug effectiveness at the targeted sites with the ability to sustain drug release 
over time, which increases patients’ compliance. In addition, targeted drug carriers also 
minimize the harmful side effects generally caused by systemic administration of highly 
potent drugs. Regarding both conceptual and practical benefits, many variants of vascular 
targeting carriers have been investigated for therapeutics in cancer as well as in pulmonary 
and cardiovascular diseases [1-4]. One major role that the vascular wall and its endothelial 
lining play in human physiology is the regulation of inflammation response. The regulated 
expression of leukocyte adhesion molecules during inflammation and their specificity 
provides a way for targeting therapeutics to the vascular wall in human cardiovascular 
diseases. Moreover, in order to sustain the ability of drug release over time, a carrier must 
survive through the circulation system and travel to a specific site without being filtered by 
reticuloendothelial system (RES) or coalesce in the vessel network. 
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Carriers such as polymer particles, liposome, dendrimers, polymersomes and 
microbubble have been explored for diagnostic and therapeutic approaches [1, 4]. Conjugated 
antibody and other targeting moieties provide specific targeting to molecules expressed on the 
surface of the cell to enhance a drug therapeutic effect. In addition, biological parameters 
including hemodynamics such as shear stress and flow pattern also impact the ability of 
targeted carriers to reach a specific tissue [5].  However, little attention has been given to 
understanding the fluid mechanic forces akin to blood flow dynamics (hemodynamics) that 
would provide a concrete ground of understanding such processes and connections in the 
pathogenesis of diseases. Therefore, carrier design features, not only their chemistry, avidity, 
carrier concentration, targeting molecule, but also hemodynamic properties (rheology, shear 
rate and flow patterns) and physical properties (size and shape) should be considered as key 
to the design of a delivery system with optimal targeting properties.   
1.1.1 Vascular-Targeted Drug Carrier Design  
   There are several criteria that need to be considered in order to design an effective 
vascular-targeted drug carrier including targeting property, hemodynamics and physical 
property.   
1.1.2 Targeting Property (targeting molecule on drug carrier) 
Endothelial cells represent a significant target for therapeutic invention in 
numerous acute and chronic diseases; thus, the optimization of targeted delivery of 
therapeutics to vascular wall represents an important medical goal [1, 3, 4]. However, most 
of pharmaceutics lack intrinsic affinity to target cells, and exhibit rapid clearance from the 
blood. These limitations can be surmounted by coupling drug carriers to targeting vectors, 
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such as antibody or protein, where they will recognize an expressed molecule on the cell 
surface at the sites of disease.  
In cardiovascular disease, leukocytes, triggered by inflammatory signals, 
accumulate at the lesion site.[6]. During this process, leukocytes, mainly monocytes and 
neutrophils, roll and adhere on the vascular wall via surface expressed ligands, e.g. P-
selectin Glycoprotein Ligand 1 (PSGL-1), which interact with endothelial-expressed 
selectins for initial capture and rolling action and Intercellular Adhesion Molecules 
(ICAM), which leads to firm adhesion on the endothelium wall. According to their specific 
and regulated expression, the selectin and other endothelial-expressed leukocyte adhesion 
molecules are suitable for targeted delivery of therapeutics to the vascular wall. Drug 
carriers can be designed to mimic leukocyte adhesion by conjugating neutrophil adhesion 
ligands or antibodies binding to endothelial expressed molecules to the surface of drug-
loaded carriers [7-9].  
According to previous studies, the multiple-receptor targeting, both selectin and 
ICAM, has higher efficiency than the single targeting receptor alone. This confirmed the 
similarity in adhesion cascade of polymeric particle and leukocyte to endothelial cell [8, 
9]. One appropriate set of ligands for conjugation on polymeric particles interacting with 
the multiple-receptor on endothelial cell are Sialyl-LewisA or X (sLeA/X) and anti-ICAM-1 
[10, 11]. sLeA/X, a sialylated fucosylated carbohydrate naturally found on PSGL-1, is 
selected due to its fast on-rate and off-rate characteristic, whereas anti-ICAM-1, which has 
a low on-rate and off-rate, can bind to ICAM-1 with strong binding and cause firm 
adhesion. 
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1.1.3 Hemodynamics Property 
 Blood flow dynamics 
 In order to enhance the efficiency of the drug carrier to the targeted site, carriers 
must be able to survive in blood circulation and migrate through the blood cell core layer 
to the vascular wall. Hemodynamics, the movement of blood cells in the circulatory 
system, is enforced by flow dynamics that can be changed by the characteristic of blood 
vessel [12-14]. Physiological blood flow in most vessels has an unsteady flow pattern 
depending on the size and location of the vessel. The cyclic heart pump also creates a 
pulsatile condition in most arteries[15]. At the curve and bifurcation vessel, the secondary 
flows can be generated in recirculating flow or vortex pattern which might enhance local 
shear stress to the luminal endothelial cell and induce adhesion of active platelets and 
WBCs causing thrombosis and atherosclerotic plaques, respectively[15-17]. Much 
research show that flow pattern and flow velocity play an importance role in the initiation 
and enhancement of the adhesion of platelets to the vascular wall [18, 19]. They found that 
the platelet adhesion is larger in steady flow than in pulsatile flow, and high share stress 
also can increase platelet adhesion[18]. Therefore, this behavior could be manipulated to 
optimize the binding efficiency of a drug carrier in blood flow as well, particularly, at the 
atherosclerotic plaque area.   
 Notably, to date, only few investigators have explored this relationship between 
blood flow dynamics and the adhesion of a vascular-targeted drug carrier that could 
provide a useful application in imaging or therapeutics of cardiovascular disease.   
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Cell-free layer in blood vessels   
 The cell free layer near the vascular wall occurs due to the tendency of RBC 
aggregation to migrate away from the vessel wall by cell-cell interaction, deformability 
and asymmetric shapes of RBC [20]. The formation of RBC core layer in a flow stream is 
influenced by several factors: extrinsic factors, including component of suspending media 
(e.g. plasma, buffer), hydrodynamic forces and dimension of flow system; intrinsic factors, 
including component of cell types (RBC, WBC and platelet), size and shape of RBC 
(species or age); and hematocrit [21]. Recently, the formation of the cell-free layer in the 
microcirculation has gained interest due to it contributions to the rheological properties of 
blood in arterioles and venules [22] and distribution of red blood cells in the capillary 
network [23].       
 The width of the cell free layer is mainly dependent on the vessel diameter. 
According to Kim and colleagues [24], it was found that the cell-free layer in rat arterioles 
increased slightly in the vessel range of 10-20 µm. diameter, but gradually decreased as the 
diameter increased in the 20-50 µm range. While Yamaguchi et al. [25] found that the cell-
free layer formation in cat brain microvessels  (arterioles and venules) doesn’t depend on 
vessel diameter in the range of 30-86 µm diameter.  Other factors that need to be considered 
are the relationship between mean flow velocity and RBC aggregation. Without the RBC 
aggregation condition, the width of the cell-free layer increase with flow rate due to 
enhanced axial migration of RBC high shear rate. However, RBC aggregation is the main 
factor that impacts the layer formation at low shear rate [24].   
 Hematocrit, one of the most important rheological factors that influence flow 
resistance in microcirculation, also majorly effects the formation of the cell-free layer due 
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to the volume fraction occupied by the RBC core layer in the vessel. The RBC core layer 
width is inversely related to the cell-free layer. In addition, the interactive force between 
RBC will be altered with increased hematocrit counteracting axial migration of RBC, 
which decreases the cell free layer width and its variation [26]. 
 Although the formation of this layer in vitro and in vivo has been of interest for 
many years, little information on the cell-free layer in terms of carrier delivery and cell 
adhesion in the microcirculation has been available due to the limitation of measurement 
techniques and the complexity of mimicking physiological microcirculation conditions.       
Red blood cell size     
 Beside hematocrit, one of the main factors enhancing platelet adhesion to the vessel 
wall is the RBCs size [27, 28].  Due to the potential role of RBCs size in enhancing platelet 
adhesion, the slightly different animal species with various size of RBCs in various animal 
species [29] may have an impact on the adhesion of a vascular-targeted drug carrier as well. 
Nowadays, only few studies have investigated the differences between animal and human 
blood rheology that could affect on the margination of blood cells and also a vascular 
targeted carrier. Grabowki et al. claimed that the significant differences in platelet adhesion 
were observed in several mammalian species which could be due to the variation in size of 
RBC in these different species [28]. This could be explained by the presence of a 
“skimming layer” or “cell free layer”. In blood flow, the RBCs mainly occupy in the center 
of the flow, which results in the cell free layer of platelet rich plasma at the vessel wall. If 
the RBCs are large, platelets simply migrate into the cell free layer region by RBCs-
platelets interaction resulting in an increase in platelet concentration and an increase in 
platelet adhesion as well. On the other hand, the small RBCs are expected to be more 
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equally mixed with the platelets and no RBCs induced platelet transport mechanism occurs, 
which cannot increase platelet adhesion.  
Existing studies in the literature focus only on RBC size with platelet adhesion. 
However, it is still not clear how different RBC size along with other blood cell components 
can affect to the binding efficacy of a vascular-targeted drug carrier in different size and 
material types.               
1.1.4 Physical Property 
Geometrics of Drug Carrier 
  For the general vascular targeting system in atherosclerosis, the carriers are 
transported by blood flow and interact by specifically binding (ligand-receptor) and non-
specifically binding (electrostatic and steric interactions) to the vessel walls, seeking the 
diseased lesion [5] as the final objective. The intravascular delivery of a carrier can be 
divided into three steps:  margination, adhesion and cell internalization [30]. The role of 
the physical properties of particle (size and shape) is important in each of these steps. 
 In general, leukocyte and platelet margination (localization and adhesion) to the 
vascular wall require interaction with red blood cells in blood flow. Thus, a high 
marginating drug carrier is one designed to move preferentially in close proximity to the 
blood vessel walls by process of escaping the red cell core and efficient lateral drifting of 
the particle to the wall once in the cell-free layer [31]. Whereas red blood cells have the 
opposite behavior to margination by accumulating preferentially within the core of the 
vessel, staying larger in macro-circulation, which is described as plasma skimming effect 
and the formation of a cell free layer [32]. Therefore, in order to be efficient drug carriers, 
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they would break through the RBCs core layer to accumulate in the cell free layer where 
an almost laminar flow is observed [33]. According to Goldmann et al., the motion of 
spherical particles in linear laminar flow does not show lateral drift unless applying an 
external force, such as gravitational or magnetic [34], while non-spherical particles show 
more complex motion with tumbling and rolling which can be broken to control their 
margination without any lateral external forces. The longitudinal, lateral forces and torque 
by blood flow depend on the size, shape, orientation of the particle to the stream direction 
and changes over time during transportation [35, 36]. Based on the previous study, it has 
been shown that the lateral drifting velocity is related to the carrier’s aspect ratio; the rod 
particle can be rotated and translated downstream drifting laterally from one side to the 
other side of the capillary, which tends to marginate more than spherical particles [35].  
 Adhesion to the vascular walls is dependent upon the balance of ligand-receptor 
interaction, which is the density of ligand molecule over the particle surface; and receptor 
molecules expressed at the cell membrane; and detaching forces such the shear stress at the 
blood vessel walls. Moreover, size and shape also have an influence on carrier adhesion: 
for submicron particles, the hydrodynamic force is small but the area of interaction at the 
particle/cell interface is smaller, leading to small number of ligand-receptor bonds 
available for capture that can withstand detachment forces.  For the large particles, the 
number of ligand-receptor bonds that can be formed grows but hydrodynamic force also 
grows even more [37]. Chareonphol et al. [38] elucidated the potential role of 
hemodynamics and size in prescribing the binding efficiency of vascular-targeted spherical 
carriers in flow via parallel plate flow assays. Specifically, spherical particles with 
diameters ranging from 200 nm up to 5 µm conjugated with sialyl Lewis (sLeA) were 
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evaluated for their ability to effectively bind activated endothelial cells (aECs) from blood 
flow. It was found that spherical particles with 2-5 µm range display significantly better 
margination to the wall at intermediate high shear rate and channel height than the sub-
micron sized sphere. 
 However, the most recent studies about the margination and adhesion of carrier 
have been observed with assays in the absence of blood cells particularly RBC and WBC. 
Likewise very few studies have been observed in animal model and micro-vascular systems.     
Plasma protein corona 
For administered drug delivery system, prolonging blood circulation time with low 
blood clearance rate is advantageous. However, it is known that biomaterial properties 
effect their protein corona formation, which is recognized by macrophages and rapidly 
clearance in the reticuloendothelial system (RES). In biological fluids (plasma or 
otherwise), a range of protein can associate with vascular drug carriers, which forms a 
“protein corona” around the particle that defines the biological character of the particle. 
The protein corona formation depends on the physicochemical properties of a targeted drug 
carrier and biomaterial such as size, charge, material type, curvature and targeting moieties 
on their surfaces [39-41]. 
Some studies have found that for copolymer, gold, or other metal nanoparticles with 
various diameters, the amount of absorbed protein on surface varied with size and surface 
curvature, and the qualitative changes of protein also depend on the size of the particles in 
the obtained corona protein[39, 42, 43]. The potential explanation is a larger ratio of surface 
to volume which allows more protein to bind to smaller particles than to particles of larger 
sizes, and total surface area differences [39, 42]. Moreover, some investigators also pointed 
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out that nanoparticles with different material and different sizes are associated with 
different corona proteins [44]. 
A few studies have shown that corona protein interferes with the ligand-receptor 
interaction on particles [45-47]. Sobcyznski et al. [42] show that the negative plasma 
protein effect  on adhesion of PLGA particle is dependent on targeting ligand density along 
with specific blood donors under physiological blood flow. Additionally, some studies also 
claim that PEGylation of nanoparticle reduce the plasma protein corona allowing the 
particles to avoid clearance in the RES and prolong circulation time [48, 49].    
We have not yet explored how the plasma protein in different animal species affects 
protein corona formation on various material surfaces and also affects on VTCs adhesion 
under blood flow condition. 
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1.2 Organization of the dissertation 
This dissertation thesis consists of 6 chapters. 
Chapter 1 introduces background and significance, literature review and the scope 
of my experiment works. 
Chapter 2 evaluates the role of size and shape in the capacity for a vascular-targeted 
carrier system to bind inflamed endothelial cells over plaque using ApoE -/- mice with 
developed atherosclerosis. Specifically, we investigated the adhesion levels along mouse 
aortas of ellipsoidal and spherical polystyrene particles targeted to the inflammatory 
molecules E-selectin and VCAM-1. Additionally, we also studied the biodistribution of 
targeted and untargeted particles in various range of size and shape, particularly, in major 
organs. For all studies, particles were injected via tail-vein and a 30-min circulation time. 
Chapter 3 investigates the role of particle size, along with hemodynamics (blood 
shear rate and vessel size) and hemorheology (blood hematocrit) on the capacity of spheres 
particle to marginate to inflamed endothelium in a microfluidic model of human 
microvessels. In more detail, we use microfluidic chambers that comprise of flow channels 
with dimensions on the order of human arteriole and venule diameters with an endothelial 
wall to evaluate the margination of spherical model VTCs from blood flow in the human 
microcirculation. Specially, 200 nm, 500 nm, 2 µm and 5 µm polystyrene spheres with 
their surfaces conjugated with sialyl lewis A (sLeA), a ligand specific to E-selectin 
expressed by inflamed endothelial cells (ECs). The efficiencies of particles were evaluated 
for their ability to localize and bind to activated ECs from human blood flow in 
microfluidic channels of 28 and 43 µm heights, allowing us to understand the behavior of 
particle under micro-circulation.  
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Chapter 4 investigates the role of hemorheology (RBC dimension) of various 
animal models and human on dictating the binding efficiency of spherical VTCs at the wall 
in physiological blood flows. Specifically, the adhesion of sLeA-coated particles, 0.2, 0.5, 
2 and 5 µm, to inflamed endothelial cells monolayers were conducted via a parallel plate 
flow chamber assay (PPFC). Particle binding was observed in RBCs-in-buffer (washed 
RBCs suspended in saline at 40%Hct) and whole blood from different animals species and 
human: rabbit, pig and mouse. The flow assays were studied under simple laminar and 
disturbed blood flow (i.e. pulsatile and recirculating flow). 
 Chapter 5 investigates the potential role of different animal plasma proteins and 
material types in dictating the adhesion efficiency of both micro and nano sphere to the 
vascular wall model from blood flow via in vitro assays. Specifically, PS, PLGA, silica 
and titanium particles were used as vascular-targeted carriers (VTCs) model in this study. 
We characterize the adhesion of sLeA conjugated particles to inflamed endothelial cells in 
laminar blood flow via a parallel plate chamber (PPFC) from different animal species 
(mouse, rabbit, porcine and human). The experiments were conduct in various blood 
suspensions (saline buffer, viscous buffer, plasma) compared to whole blood. The result 
from this chapter would raise awareness of the possible difference in result from animal to 
represent human.  
 Chapter 6 draws the conclusion and summary the important result from this 
dissertation to the field of study, and also proposes the new topics for future research.  
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CHAPTER 2 
IN VIVO EVALUATION OF VASCULAR-TARGETED 
MICROPARTICLE DRUG CARRIER IN ATHEROSCLEROSIS  
Abstract 
Vascular-targeting remains a promising strategy for improving the diagnosis and 
treatment of coronary artery disease (CAD) by providing localized delivery of imaging and 
therapeutic agents to atherosclerotic lesions. In this work we evaluate how size and shape 
affects the capacity for a vascular-targeted carrier system to bind inflamed endothelial cells 
over plaque using ApoE -/- mice with developed atherosclerosis.  We investigated the 
adhesion levels along mouse aortas of ellipsoidal and spherical particles targeted to the 
inflammatory molecules E-selectin and VCAM-1, as well as the biodistribution of targeted 
and untargeted particles in major organs following injection via tail-vein and a 30-min 
circulation time. We found that targeted ellipsoidal microparticles adhered to mouse aortas 
at higher levels than microspheres of similar volume, particularly at segments that 
contained atherosclerotic plaques. Moreover, both ellipsoidal and spherical nanoparticles 
displayed the same minimal adhesion levels compared to both types of microparticles 
evaluated, likely due to poor localization of nanoparticles to the vessel wall in blood flow. 
We found that microparticles targeted to plaque-associated inflammation were retained at 
higher levels in the lungs than untargeted particles, largely due to molecular interaction 
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with the pulmonary endothelium.  The level of the mechanical entrapment of ellipsoidal 
microparticles in the lungs was also not significantly different from that of microspheres 
of the same volume despite a ~3-fold higher major axis length for the ellipsoids.  Therefore, 
particle shape and size should be considered in the design of carrier systems to target 
atherosclerosis, as these parameters can be tuned to improve carrier performance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Content of this have been published as Namdee K, Thompson AJ, Golinski A, Mocherla S, Bouis 
D and Eniola-Adefeso O. In vivo evaluation of vascular-targeted spheroidal microparticles for 
imaging and drug delivery application in atherosclerosis. Atherosclerosis. 2014; 237(1): 279-286.   
* This work is collaborated with Dr. Alex J Thompson as equal contribution.    
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2.1 Introduction 
 Vascular targeting remains a promising avenue for localized delivery of imaging 
and/or therapeutic agents to the diseased vasculature in coronary artery disease (CAD), the 
consistent leading cause of mortality in the western world [1, 2]. Vascular-targeted carriers 
(VTCs) are of particular interest for the treatment of CAD because specific vascular wall 
endothelial cell receptors associated with acute and chronic inflammation (selectin, ICAM-
1, VCAM-1) play a major role in the pathology of this disease.  Naturally, these receptors 
then also provide a convenient and accessible platform for vascular targeting. Current 
vascular-targeting strategies in CAD typically involve coating injectable carriers with 
targeting moieties, e.g. antibodies or peptides, for specific interaction with the relevant 
endothelial expressed receptors, providing these carriers the ability to navigate the 
vasculature, adhere, and persist locally in the diseased tissue [3]. Overall, the ability to 
provide highly localized delivery to atherosclerotic pre-lesions or fully formed plaques in 
CAD can offer new therapeutic avenues for early diagnosis and treatment of this disease 
[4].  
 Many variants of VTCs have been investigated for use as a diagnostic or 
therapeutic, such as polymer particles, liposomes, dendrimers, and polymersomes; which 
are typically spherical with nanoscale diameters [5]. However, particle shape and size have 
recently been presented as tunable parameters for enhancing the vascular wall interaction 
of VTCs at a targeted site in the presence of blood flow [6-8].  Specifically, numerous 
mathematical and some simple flow experimental models show that ellipsoidal particles 
can display greater deposition/adhesion compared to spherical particles of the same volume 
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[9-12].  Our recent in vitro study also shows that under physiological levels of shear, prolate 
ellipsoidal (rod-like) particles targeted to inflammation display higher levels of adhesion 
compared to spheres in the presence of human red blood cells (RBCs) in parallel plate flow 
chamber (PPFC) assays, provided that the equivalent spherical diameter of the rods is ≥ 1 
µm [13].  To our knowledge, no in vivo study has been performed to compare adhesion of 
spherical and ellipsoidal polymer VTCs within the context of targeting atherosclerotic 
plaques in CAD.  The areas of the vasculature vulnerable to atherosclerosis tend to be large 
vessels (on the order of centimeters), which make the successful localization of VTCs to 
the vascular wall increasingly important in determining their overall performance. Further, 
these atheroprone areas tend to exhibit pulsatile and disturbed blood flow profiles which 
are very different in terms of hemodynamics compared to the microvasculature, where 
much of the previous vascular targeting research has been focused [14].  In this study, we 
evaluate the role that the size and shape of particles has on their capacity to effectively 
reach and bind to inflamed aorta using a mouse model of atherosclerosis.   Specifically, we 
investigated the adhesion levels of dual, E-selectin and VCAM-1,-targeted prolate 
ellipsoidal and spherical particles along sections of the aorta from the aortic root to the iliac 
branches, and the effect of the targeting ligands on the biodistribution of spherical and 
ellipsoidal particles in major organs. E-selectin and VCAM-1 are proteins known to be 
overexpressed by endothelium in atherosclerosis [15-17]. A dual targeting of both E-
selectin and VCAM-1 is employed based on previous publications that suggest in vivo 
selectivity to ECs over plaque in ApoE-/- mice is greatest when both VCAM-1 and selectin 
were targeted.[18, 19] We found that targeted rod-shaped microparticles adhered to mouse 
aortae at overall higher levels than spherical microparticles, particularly at segments of the 
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aorta that contained developed or developing plaques.  There was no difference in the 
adhesion of rod-shaped and spherical nanoparticles, which was minimal compared to the 
adhesion of microparticles.   
2.2 Methods 
2.2.1 Preparation of vascular-targeted particles 
Fluoresbrite® YG carboxylate polystyrene spheres were purchased from 
Polysciences, Inc (Warrington, PA). Prolate ellipsoidal (rod-shaped) particles were 
prepared using a previously described polymer film stretching method [13]. Spheres and 
rods with the same equivalent spherical diameter (ESD), and thus volume, were used in 
this study (500 nm or 2 µm ESD).  Unless otherwise stated, 2 µm ESD rods have aspect 
ratio (AR) = 4 and 500 nm ESD rods have AR = 6. The dimensions of the particles used to 
test the effect of AR on particle adhesion are shown in Supplemental Table 1.  Rods and 
spheres were conjugated with Neutravidin® Biotin-Binding Protein (Thermo Scientific), 
which is used a platform to conjugate biotinylated targeting ligands as previously described 
[3]. In this study, a multiple ligand system was used to target vascular inflammation.  The 
two targeting ligands used were biotinylated sialyl Lewis A (sLeA) for binding to E-selectin 
and biotinylated rat anti-mouse CD106 (aVCAM-1) for binding to VCAM-1.  On the day 
of injection, VTCs were coated with a combination of sialyl Lewis a (Glycotech; 
Gaithersburg, MD) and aVCAM-1 (BD Pharmingen).  Unless otherwise stated, VTCs were 
saturated at a ratio of 30% sLeA and 70% aVCAM-1, as this ratio was previously 
determined to be advantageous for adhesion to inflammation [20]. Particles used in the 
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untargeted control study were prepared in the same way, except their surfaces remained 
carboxylated. 
2.2.2 Murine model and in vivo assay 
The procedures of animal experiment were approved by Unit for Laboratory 
Animal Medicine, The University of Michigan. Twenty-five homozygous ApoE-/- mice 
and twenty-five wild type at 8-10 weeks old were purchased from Jackson Laboratories 
(Bar Harbor, ME). Mice were fed a normal diet for 20 weeks.   Mice with an average weight 
of 28 grams were randomly assigned into five groups of five animals, and VTCs were 
injected via tail vein at a dosage of 20 x 106 particles in 200 µl of in phosphate buffered 
saline (PBS) /mouse. 30 min after injection, mice were anaesthetized with 100 µl of a 
mixture of 35% ketamine and 5% xylazine in PBS. Additional anesthesia was administered 
as necessary. Blood was drawn via cardiac puncture from the left ventricle using heparin-
coated syringe. Following blood draws, the right atrium was nicked and the vasculature 
was perfused with ice-cold PBS by injection into the puncture site at the apex of the left 
ventricle. The lung, liver, spleen, and kidney were harvested and snap-frozen in liquid 
nitrogen. Consequently, the heart and aorta were perfused again with ice-cold 4% 
paraformaldehyde (PFA) in PBS at pH 7.5. Whole mice were preserved in 4% PFA until 
aorta isolation.  The aorta were excised from the aortic arch to the iliac branches, including 
the renal branches and celiac branch, and kept in 4% PFA in PBS. For each heart, the apex 
was removed in order to increase the penetration of solution into tissue, and placed in ice-
cold 4% PFA in PBS for 3 hours. The heart was washed 3 times for 15 minutes with PBS 
before being soaked overnight with 30% sucrose.  The heart was embedded in O.C.T. 
embedding medium and snap-frozen before cross-sections of the aortic root were collected.   
26 
 
2.2.3 Quantification of particle adhesion in vivo 
  After the fixation process, the aorta was cleaned of fascia and fat deposits adjacent 
to the vessel before it was excised into segments along the full length including aortic 
arches, abdominal branches and iliac branches (1000 µm -1500 µm in length/segment). 
Each segment was tracked by number and position.  Aortic segments were bisected and 
mounted open en face on glass slides by 4% PFA, and coverslips were sealed using nail 
polish agent. The aorta slides were imaged using a Nikon TE 2000-S Inverted Microscope 
and an attached Photometric CoolSNAP EZ digital camera with a Sony CCD sensor. The 
en face images were quantified using Metamorph® software by counting number of 
adherent particles on both endothelial area and plaque area. The microparticles were 
quantified using a 20 X objective while the nanoparticles were quantified with a 40 or 60 
X objective. For each group of mice, we averaged the number of adherent particles along 
the entire aorta. Standard error bars are plotted and statistical significance in the data was 
determined by one-way ANOVA with Tukey post-test (a value of p < 0.05 was considered 
statistically significant).  To account for variation in plaque density and inflammation 
levels across different mice, particle adhesion was normalized to the adhesion of 500 nm 
diameter spherical particles.  Particle adhesion in the aortic root was imaged by removal of 
the apex of the heart and sectioning into approximately 130 cross-sections of 6 μm each 
prepared from the base of the aortic root to the ends of the aortic valve leaflets using 
cryostat at −20°C.  The sectioned tissues were mounted on gelatin-coated microscope 
slides. The slides were allowed to dry at room temperature for 30 min. Images were then 
captured by fluorescence microscopy to qualify particles adhesion on aortic root.  
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Subsequently, the slides were stained with hematoxylin and eosin, and mounted with 
permount.  Mounted tissues were then reimaged by light microscopy.   
2.2.4 Scanning electron microscopy (SEM) 
 Aortic root samples were also prepared by a freeze dry process for SEM imaging. 
The samples were immersed in liquid nitrogen and placed in a vacuumed desiccator for 2 
hr. Then, the samples were sputter coated with gold and imaged using a Philips XL30FEG 
SEM (EMAL, University of Michigan) at 4000x and 8000x magnification.   
2.2.5 Quantification of biodistribution in organs 
 Harvested and snap-frozen organs (lung, liver, spleen and kidney) were stored at -
80C° until ready to analyze for particle accumulation. Organs were thawed and multiple 
samples from each organ were weighed and homogenized in 1 ml of PBS+/+.  The 
concentration of particles in each homogenized solution was quantified using a 
hemocytometer under a fluorescence microscope. For the lungs and liver, only a part of the 
organ was harvested and analyzed for particle accumulation. The same area of these organs 
was used in all animals. For the lungs, a portion of left lobe with an average sample weight 
37 ± 3.5 (S.E.) or 163 ± 6.7 mg was used for assays with ApoE-/- or wild type mice, 
respectively. For the liver, a portion of the left lobe weighing 110 ± 3.9 (S.E.) or 320 ± 7.5 
mg was used.  The whole organs were used for analysis of particle accumulation in the 
spleen and kidney. Particle accumulation was calculated as % injected dose/gram organ (% 
ID/g), and each data point represented an average of at least 5 samples. Standard error bars 
are plotted and statistical significance in the data was determined by one-way ANOVA 
with Tukey post-test (a value of p < 0.05 was considered statistically significant).   
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2.3 Results 
2.3.1 Binding efficiency along the aorta  
 Adhesion of spherical and prolate ellipsoidal (rod-shaped) vascular-targeted 
particles (VTPs) was quantified along the aortic tree of ApoE -/- mice following 
intravenous injection via the tail vein and a 30-minute subsequent circulation time.  
Particles had equivalent spherical diameters (ESD) of either 500 nm or 2 µm with aspect 
ratios of either 1 (spheres), 6 (500 nm rods) or 4 (2 µm rods).  Figure 1 shows representative 
fluorescent and H&E images of sections of the aortic root for mice injected with dual-
targeted spheres and rods with either 2 µm or 500 nm ESD.  As shown in these images, 
VTPs are successfully bound to the aorta after a tail-vein injection.  Figure 2-2A shows the 
average cumulative particle adhesion along the entire length of the aortic tree normalized 
to the adhesion of 500 nm spheres, from the ascending aorta to the iliac branching points. 
Particles with 2 µm ESD displayed significantly higher adhesion densities, at least 4 fold, 
compared to particles with 500 nm ESD.  When adhesion data is normalized to the particle 
volume (relevant for drug loading), the cumulative volume delivered by adherent 
microparticles is ~500-1500 fold higher than the volume of adherent nanoparticles 
depending on particle shape (Supplemental Figure 2-1). Sample images of fluorescent 
microparticles bound to the aorta are shown in Supplemental Figure 2-2. Nanorods 
displayed no increased adhesion compared to their equivalent 500 nm diameter spheres. 
Control experiments with targeted 2 µm spheres injected into wild type mice or 2 µm IgG-
coated particles (spheres or aspect ratio 4 rods) injected into ApoE-/- mice show minimal 
accumulation in the aorta (Figure 2-2B), suggesting that the high adhesion of targeted 
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microparticles observed in the aorta in ApoE-/- mice are due to the expression of the 
targeted inflammatory molecules by the endothelium.   
 It is established that atheroprone areas of the aorta are typically near vessel 
bifurcations or curvature, whereas the blood flow profiles along straight sections of the 
aorta tend to be atheroprotective.  Therefore, we also quantified the adhesion density of 
targeted particles along different sections of the aorta from the ascending aorta to the iliac 
branches.  At each section investigated, the adhesion density of 2 µm ESD rods was greater 
than or equal to the adhesion of equivalent spheres (Figure 2-2C).  Interestingly, the 
adhesion density of targeted microrods relative to microspheres and nanoparticles was 
greatest around the combined area of the brachiocephalic, right common carotid (RCC), 
and right subclavian (RS) branching points nearby the aortic arch, followed by the thoracic 
aorta and to a smaller extent the descending aorta.  Visual inspection revealed 
developing/developed plaques near many of the branched and curved regions of the 
vasculature (Supplemental Figure 2-3).  Qualitatively, adhesion of targeted particles was 
higher on or near these regions of plaque formation. As shown in Figure 2-3, a 
representative Hoecsht (nucleus) and wheat germ agglutinin (plasma membrane) staining 
of a segment of the aorta with visible plaque, more microparticles were bound around the 
periphery of the developing plaque than on the top.  Overall, adhesion was minimal for 
nanoparticles throughout the aorta compared to microparticles, even in areas where very 
high levels of inflammation are expected. 
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Figure 2-1 Fluorescent and H&E stain images of aortic roots adhesion of 
micro/nanoparticles of different size/shape on atherosclerotic plaque at 20X magnification. 
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Figure 2-2 (A) Ratio of the adhesion of sLea and anti-VCAM coated particles on ApoE -/- 
mouse aortae following 30 min circulation via tail vein injection. Adhesion data shown is 
normalized to the adhesion of 500 nm diameter spheres. AR = 6 and 4 for rods with ESD 
of 500 nm and 2 µm, respectively (* = p < 0.05 with respect to 2 µm microspheres and 
n.s.= not significant via one-way ANOVA. n ≥ 5). (B) Ratio of the adhesion of sLeA and 
anti-VCAM targeted 2 μm spheres in wild type mouse aortae or of IgG-coated 2 μm spheres 
and rods (AR4) in ApoE −/− mouse aortae following 30 min circulation via tail vein 
injection (C) Ratio of particle binding (normalized to the average number of 500 nm ESD 
spheres bound per segment) of sLeA and anti-VCAM coated particles to the endothelium 
in 12 segments along mouse aorta. (* = p < 0.05 with respect to 2 µm microspheres. n ≥ 
4). 
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2.3.2 Effect of aspect ratio (AR) on particle adhesion 
In order to determine the effect that aspect ratio has on targeting ability, targeted 
rods of three different ARs (2, 4, 9) with 2 µm ESD as well as 500 nm and 2 µm spheres 
were prepared.  Figure 2-4 shows the SEM images of the 2 µm ESD rods and their 
equivalent spheres.  Particles were injected into ApoE-/- mice via tail-vein and the total 
adhesion along the aortae was quantified for each particle shape as before.  The adhesion 
of the AR4 rods was the highest (~3 times higher) relative to their equivalent microspheres 
as shown in Figure 2-5.  Adhesion of AR2 rods was roughly the same as 2 µm spheres, 
likely because of the relatively small difference in shape and surface area between these 
two shapes.  Adhesion of AR9 rods was statistically the same as the 2 µm spheres and 
lower than that of AR4 rods despite having a higher contact surface area, likely due to 
entrapment in the capillaries as AR9 rods have a major axis length of roughly 9 µm.   
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Figure 2-3 Representative images of aortic arch segments (with atherosclerotic plaque 
present) with adhesion of 2 µm ESD sphere (A and B) and 2 µm ESD rod (C and D) at 
20X and 60X magnification, respectively, qualitatively showing the increased adhesion of 
rods particularly near the periphery of plaques (Blue = nucleus stained by Hoechst, Red = 
plasma membrane stained by Alexa Fluor conjugate of wheat germ agglutinin and Green 
= fluorescent particle). 
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Figure 2-4 SEM image of 2 µm ESD polystyrene (A) spheres, (B) AR-2 rods, (C) AR-4 
rods, and (D) AR-9 rods used to test the effect of aspect ratio on particle adhesion on ApoE 
-/- mouse aorta after 30 min circulation via tail vein injection. 
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Figure 2-5 Ratio of the binding (normalized to 500 nm ESD sphere) of sLeA and anti-
VCAM coated particles of various AR on ApoE -/- mouse aortae after 30 min circulation 
via tail-vein injection. (* = p < 0.05 and n.s.= not significant via one-way ANOVA. n ≥ 3). 
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Figure 2-6 (A) Biodistribution of sLeA and anti-VCAM coated spheres (500 nm or 2 µm 
diameter) and rods (2 µm ESD, AR4) in ApoE -/- mice following 30 min circulation via 
tail-vein injection. n≥5 (B) Biodistribution of untargeted spheres (2 µm diameter) and rods 
(2 µm ESD, AR4) in wild type mice following 30 minute circulation via tail-vein injection. 
(* = p < 0.05 relative to 2 µm spheres and # = p < 0.05 relative to the 500 nm spheres via 
one-way ANOVA. n ≥ 4). 
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2.3.3 Particle accumulation in different organs 
Major organs were harvested from animals injected with targeted particles to 
quantify the biodistribution of the microrods with the top performing aspect ratio, AR4, 
relative to its equivalent sphere and nanospheres.  Figure 2-6A shows the accumulation of 
targeted particles in the lung, liver, spleen, and kidney.  Blood collected following a 30-
minute circulation time contained negligible amounts of particles (data not shown).   
Targeted AR4 microrods were retained at a higher level in the lungs than 2 µm or 500 nm 
diameter spheres.  These same rods were retained at either equal or significantly lower 
levels than micro/nanospheres in the other organs, potentially because their higher level of 
first-pass lung accumulation and adhesion to the aorta reduces the amount available to 
accumulate elsewhere.  The 500 nm spheres accumulated at higher levels in the liver than 
the larger microparticles, and there was no appreciable difference in the splenic 
accumulation of micro and nanoparticles.  Retention of particles in the kidneys was low, 
as particles larger than about 50 – 100 nm are not expected to be removed from blood via 
glomerular filtration.  The higher accumulation of targeted rods in the lungs may be due to 
physical entrapment of rods (major axis = 5.6 µm) in the small capillaries of the lungs or 
due to the surface targeting ligands allowing molecular interaction to increase adhesion of 
particles to lung endothelium.  To investigate this further, uncoated rods and spheres were 
injected into wild type mice via tail-vein and allowed to circulate for 30 minutes before the 
mice were sacrificed and organs harvested. As shown in Figure 2-6B, retention of 
untargeted microspheres and the AR4 microrods in the lungs was about 87% and 93% 
lower, respectively, than targeted particles of the same size and shape.  Meanwhile, 
retention of untargeted microspheres and microrods was about 60% and 280% higher in 
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the liver, and about 81% and 140% higher in the spleen, respectively, than the equivalent 
targeted particle. When each dataset presented in Figure 2-6 is normalized to the density 
of each particle type accumulating in the lungs, the targeted microspheres were found to 
accumulate in similar amounts in the lung, liver and spleen while targeted microrods 
accumulated primarily in the lungs (Supplemental Figure 2-4).  However, untargeted 
microspheres and microrods both displayed the majority of accumulation in the liver and 
spleen. 
2.4 Discussion 
Physical property of particle, such as particle shape and size, is known to be an 
important parameter that can be tuned to affect the circulation time, biodistribution, 
adhesion, internalization, and intracellular trafficking of vascular-targeted drug carriers 
[21-31].  This study shows that the size and shape of vascular-targeted carriers plays a role 
in prescribing their adhesion to atherosclerotic area and accumulation in major organs in 
mouse model. In order for particles to successfully adhere to inflamed endothelium, they 
must be able to effectively marginate to the vessel wall as well, which is comparable to 
how circulating WBCs and platelets are able to localize to inflamed endothelium even in 
large diameter vessels.  Previous works have revealed that particle size plays a crucial role 
in the ability or inability of a particle to preferentially marginate in the presence of human 
blood components (RBC, plasma) using in vitro blood flow assays [3, 8, 13, 20, 32, 33].  
Generally, particles that have diameters less than about 2 µm do not segregate through 
RBC core to the cell-free layer, and then slightly adhere to ECs at the vessel wall, in blood 
flow as efficiently as particles with diameters ≥2 µm [3, 10, 30, 32]. Instead, the study 
suggests that these submicron to nanoscale particles mostly remain in the core of flow, 
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enclosed by RBCs [8]. According to the results, we found that the adhesion of targeted 
nanospheres and nanorods of 500 nm ESD are significantly lower along the mouse aorta 
compared to microparticles. In addition, the increased adhesion of microrods to the mouse 
aorta (roughly 4 fold) compared to equivalent microspheres is similar to our previous study 
of particle localization in human blood in vitro assays which microrods (≥1 µm ESD) were 
found to adhere at higher levels than equivalent spheres [13]. This increased adhesion for 
microrods in vivo over their equivalent spheres is likely due to more favorable adhesive 
characteristics rather than improved localization to the wall, including a higher contact 
surface area and a streamlined shape to reduce drag force in the presence of blood flow 
induced shear, since no improvement was found in the localization of rod-shaped particles 
to the RBC-free plasma layer (CFL) in human blood flow in PPFC assays compared to 
their equivalent spheres [13]. The deficiency of adhesion of nanorods compared to 
nanospheres is likely due to the incapability of nanoparticles to preferentially segregate to 
the CFL, which is unrelated to their shape and the impact of higher contact surface area. 
Whereas particles on the nanometer scale may provide advantages in long circulation time 
and transmigration across the endothelium, the drawback of nanoparticles to preferentially 
adhere to the endothelium in the aorta could potentially limit their efficacy as a vascular-
targeted carriers in medium/large blood vessels.  
 “Atheroprone” are specific areas of the arterial tree predisposed to atherosclerotic 
lesion formation. These atheroprone areas including the aortic root, the curvature along the 
aortic arch, and major branching points along the arterial tree; usually are exposed to 
disturbed blood flow, characterized by high pulsatile flow but low net shear [14, 34]. The 
results shows significantly increased adhesion of microrods compared to spheres in many 
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atheroprone areas, particularly nearby major branching points in the aorta and curvature 
along the aortic arch. Particle adhesion at atheroprone was found more binding at the 
periphery of the plaque, which agrees with previously reported findings for the adhesion 
of VCAM-1 targeted polymeric particles [35].  This formation is very likely related to the 
expression patterns of the target molecules, particularly VCAM-1, which have been shown 
to persist on ECs nearby plaques more so than directly on top of plaques within ApoE -/- 
mice [15].  
 According to previous research, particle shape and size associated with presence of 
targeting ligands can affect biodistribution in mice,  [21, 28, 31, 35, 36], and then in this 
study we would like to include the biodistribution profile altered based on these parameters.  
As the result, we find accumulation of particles in the lung and liver, with accumulation to 
a lesser extent in the spleen and kidneys. We find significantly more targeted 2 µm ESD 
rods in the lungs compared to equivalent spheres, which could be a function of either (1) 
mechanical entrapment due to the longer axis length of the rod or (2) enhanced molecular 
interactions of the targeting ligands on rods with pulmonary endothelium.  Research has 
correlated accelerated pulmonary endothelial inflammation with the presence of systemic 
atherosclerosis[37], so some level of accumulation based on molecular interaction with 
targeting ligands could be occurring. Certainly, the significantly lower accumulation of 
untargeted microparticles in the lung suggests that a significant portion of the lung 
accumulation is due to molecular interaction of the targeting molecule with the pulmonary 
endothelium and would be exaggerated for the microrods versus spheres due to their larger 
surface area for contact. Interestingly, the mechanical entrapment of the AR4 microrods 
(i.e., non-targeted particles) in our study is not significantly different from that of spheres 
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despite having quite different major axis lengths (see Figure 2-6), which would suggest 
that the rods preferentially enter the capillaries in an orientation that line their major axis 
in the direction of flow.    
Finally, the overall biodistribution profile of microparticles shows preferential 
accumulation in the liver and spleen when the targeting ligands are removed from 
microparticles. This is probable due to the lower first-pass retention of untargeted particles 
in the lung (immediately following tail vein injection) and more untargeted particles 
available in circulation for hepatic/splenic clearance compared to their targeted 
counterparts. The overall observation of particle distribution in this work is agree with a 
previous study by Muro et al., which reported the accumulation of anti-ICAM targeted 
polystyrene disks in the lungs and liver of C57Bl/6 mice [21]. This study found that 
targeted micro-disks accumulated at high levels in the lungs and relatively low levels in 
the liver, and that retention of nontargeted (IgG coated) particles was diminished in the 
lungs, with a corresponding increase in liver accumulation [21]. The liver accumulation of 
microparticles in this study (%ID/g) is slightly higher than in other published reports, 
which may be due to differences in quantification techniques and also heterogeneity in the 
liver.  In this study, the left lobe of the liver from each animal was harvested after the 
animal is sacrificed and the circulatory system perfused with buffer and fixing agent.  It is 
possible that more particles were deposited in the left lobe than in the rest of the liver. It 
has been shown that “portal streamlining” can result in incomplete blood mixing causing 
variation in blood delivered to liver lobes and hence disproportionate deposition of 
particles between the two lobes [38]. Also, blood from the spleen or stomach tends toward 
the left side of the liver.[38] Furthermore, others have published in vivo studies with 
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fluorescent images that seem to suggest heterogeneous particle deposition in the liver as 
well [39, 40].  
In conclusion, the study reveals that ellipsoidal microparticles of an intermediate 
aspect ratio (AR4) with volume equivalent to 2 μm diameter spheres are higher efficient 
than microspheres with equal volume and nanoparticles at the aorta of atherosclerotic mice, 
particularly in atheroprone areas. In addition, the untargeted microrods show a similar level 
of minimal mechanical entrapment in the lung capillaries compared to their spherical 
counterparts. Thus, the ellipsoidal geometry with the appropriate aspect ratio may be an 
advantageous shape for designing drug carriers for targeting the aorta, in order to enhance 
efficiency of therapeutics or diagnostics intravenously in atherosclerosis. However, 
targeted microrods, more than microspheres and nanoparticles, are retained in the lungs at 
higher levels compared to their untargeted counterparts, likely due to molecular interaction 
with inflammatory molecules in the pulmonary vasculature of atherosclerotic mice. 
Overall, this work reveals that particle shape, particle size, and targeting moiety all play a 
role in dictating the adhesion and biodistribution profile in a mouse model of 
atherosclerosis, therefore all of these parameters should be considered when designing 
carrier systems to target this disease. 
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2.5 Supplemental Data 
Supplemental Table 2-1. Dimensions of particles used to test the effect of AR on 
particle adhesion (Figure 2-5) 
 
 
 
 
Supplemental Figure 2-1.  Ratio of volume binding (normalized to 500 nm ESD rod) of 
sLeA and anti-VCAM-coated particle binding on ApoE -/- mouse aorta after 30 min 
circulation via tail vein injection. n≥5 
 
 
 
 
Particle Shape ESD (μm) Aspect Ratio Major Axis (μm) Minor Axis (μm)
Sphere 1.00 2.07 2.07
AR-2 2.25 3.55 1.58
AR-4 4.46 5.61 1.26
AR-9 9.45 9.25 0.98
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Supplemental Figure 2-2.  Fluorescent images of sLeA and anti-VCAM-coated 2 µm 
sphere and rod (AR4) particles adhering on ApoE -/- mouse aortas after 30 min circulation 
via tail vein injection. Five sections of the aorta are shown: aortic arch, RCC, descending 
aorta and thoracic aorta.   
2 µm Sphere                                              2 µm Rod (AR4) 
Aortic arch (4X)                                
RCC (10X)                                
Descending aorta (4X)                                
Thoracic aorta (4X)                                
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Supplemental Figure 2-3. Anatomical images of en face mouse aorta with atherosclerotic 
plaque area (red) stained with O-red oil, presenting developing plaques near the 
branched/curved regions of aorta. 
 
  
Supplemental Figure 2-4. Ratio of the accumulation density in major organs (%ID/g 
organ) to the accumulation density in the lungs (%ID/g lungs) for (A) targeted and (B) 
untargeted 2 µm spheres and rods (2 µm ESD, AR4) in mice following 30 minute 
circulation via tail-vein injection. n≥4 
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CHAPTER 3 
MARGINATION PROPENSITY OF VASCULAR-TARGETED 
SPHERES IN A MODEL OF HUMAN MICROVESSELS  
Abstract 
Many variants of vascular-targeted carriers (VTCs) have been investigated for 
therapeutic intervention in several human diseases. However, in order to optimize the 
functionality of VTC in vivo, carriers’ physical properties, such as size and shape, are 
important considerations for a design that evades the reticuloendothelial system (RES) and 
successfully interacts with the targeted vessel wall. Nonetheless, little evidence has been 
presented on the role of size in VTC’s interactions with the vascular wall, particularly in 
the microcirculation. Thus, in this work, we explore how particle size, along with 
hemodynamics (blood shear rate and vessel size) and hemorheology (blood hematocrit) 
affect the capacity for spheres to marginate to inflamed endothelium in a microfluidic 
model of human microvessels. Microspheres, particularly the 2 µm spheres, were found to 
show disproportionately higher margination than nanospheres in all hemodynamic 
conditions evaluated due to the poor ability of the latter to localize to the wall region from 
midstream. This work represents the first evidence that nanospheres may not exhibit “near 
wall excess” in microvessels, e.g. arterioles and venules, and therefore may not be suitable 
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for imaging and drug delivery applications in cancer and other diseases affecting 
microvessels.  
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
* Content of this have been published as Namdee K, Thompson AJ, Charoenphol P and Eniola-
Adefeso O. Margination propensity of vascular-targeted spheres from blood flow in a microfluidic 
model of human microvessels. Langmuir. 2013, 29(8): 2530-2535.   
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3.1 Introduction  
Vascular-targeted drug delivery offers the advantage of low drug side effects and 
the ability to sustain drug release over an extended period, both of which would lead to an 
increase in patient compliance. Many variants of vascular-targeted carriers (VTCs) have 
been investigated for therapeutic intervention in several human diseases where a unique or 
an overexpression of specific biomolecules by the endothelium of the vascular wall can be 
identified, including in cancer and coronary artery disease [1-4]. However, in order to 
achieve optimum targeting, VTCs must first successfully travel from midstream of blood 
flow to the red blood cell (RBC)-free plasma layer adjacent to the vessel wall. Therefore, 
the physical properties of VTCs (e.g. size and shape) that facilitate optimal margination 
(localization and adhesion) to the vascular wall are necessary considerations in their design.   
To this end, a few works in the literature have evaluated the role of carrier size in 
the binding efficiency of VTCs to the vascular wall from blood flow. In one study, Decuzzi 
and co-workers used a theoretical model to show that spherical drug carriers with diameters 
in the range of 100 nm would have the same short margination time to the vascular wall as 
2 µm spheres [5]. However, we recently reported that 2-5 µm diameter spheres display 
significantly better margination to the wall from bulk human blood flow than nanospheres 
in channels on the order of medium to large blood vessels [6-8]. Nanospheres were found 
to exhibit minimal margination in bulk blood flow due to their significant entrapment 
within the red blood cell (RBC) core that forms when blood flows in blood vessels or 
confined channels in vitro [8]. It remains unclear, though, whether the reported trends for 
medium and large channels would prevail in the microcirculation that comprises arterioles, 
venules, and capillaries [9]. 
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Microvessels are critical for the transfer of nutrients and leukocyte diapedesis 
(extravasation) into tissue spaces.  However, these vessels are also known to be involved 
in the pathology of many human diseases, the most notable of which is cancer. Thus, 
targeted disruption of the tumor vasculature and/or localization of nanoparticles into tumor 
tissue, via the enhanced permeability and retention (EPR) effect in tumor capillaries, are 
often proposed as a strategy for cancer treatment. Though both of these targeting strategies 
typically focus on the capillaries, the majority of blood vessels in a tumor microvascular 
network have diameter greater than 20 µm (i.e. the feeding arterioles and post-capillary 
venules)[10], and are therefore likely to exhibit bulk blood flow. In this work, we use 
microfluidic chambers that comprise of flow channels with dimensions on the order of 
human arteriole and venule diameters (~ 20 - 100 µm) and an endothelial wall to evaluate 
the margination of spherical model VTCs from blood flow in the human microcirculation. 
Specially, 200 nm, 500 nm, 2 µm and 5 µm polystyrene spheres with their surfaces 
conjugated with sialyl lewisA (sLeA), a ligand specific to E-selectin expressed by inflamed 
endothelial cells (ECs), were evaluated for their ability to localize and bind to activated 
ECs from human blood flow in microfluidic channels of 28 and 43 µm height. 
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3.2 Method  
3.2.1 Microchannel fabrication 
 Microfluidic chambers (Figure 3-1A) were designed using AutoCAD software. A 
chamber template was fabricated on silicon wafers using a soft lithography technique [11]. 
This template was then silanized with tridecafluoro-(1,1,2,2-tetrahydrooctyl)-1-
trichlorosilane (United Chemical Technologies, Bristol, PA) for 1 hr at room temperature 
in a desiccator to prevent polydimethylsiloxane (PDMS) from adhering to the template. 
PDMS was poured into the mold and cured at 60°C overnight. The solidified PDMS layer 
was removed from the template. The chamber was exposed to plasma oxygen for 15 min 
to render its surface hydrophilic. The chamber length was set at 10 mm including the 2 mm 
diameter reservoirs on both ends. Two 1.5 mm pin holds were punched through on both 
ends in the reservoir areas to allow access into the channel. A vacuum network was applied 
around the chamber to allow the sealing of a glass coverslip with a monolayer of 
endothelial cells.  
3.2.2 Preparation of vascular-targeted particles  
Carboxylate-modified polystyrene spheres of 0.20, 0.51, 2.07, and 5.72 µm in size 
(Bangs Laboratories Inc., Fishers, IN) were covalently coupled with NeutrAvidin protein 
(Pierce Biotech Inc., Rockford, IL) via carbodiimide (EDAC) chemistry as previously 
described [12]. Avidin-coated spheres were conjugated with biotinylated multivalent sialyl 
Lewis A (sLeA; GlycoTech, Gaithersburg, MD) in 50 mM PBS with 1% BSA and 
resuspended in blood at a fixed concentration, 5 times 105 particles/mL, as previously 
described. A fixed targeting ligand surface density was achieved for all spheres by varying 
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ligand concentration in the conjugation solution for each particle size. Sphere surface 
ligand densities were quantified via BD FACsCalibur. A site density of approximate 1000 
sites/µm2 were used for in vitro experiments with sLeA [13]. 
3.2.3 Preparation of endothelial cell (EC) monolayer 
 Human umbilical vein endothelial cells (HUVECs) were harvested and cultured as 
described in [6]. HUVECs) harvested from fresh umbilical cords obtained from Mott 
Children's Hospital (Ann Arbor, MI) were pooled and cultured in tissue culture flasks 
pretreated with gelatin (0.2% w/v). Human umbilical cords were obtained from the U of M 
hospital under a Medical School Internal Review Board (IRB-MED) approved human 
tissue transfer protocol (HUM00026898). This protocol is exempt from informed consent 
per federal exemption category #4 of the 45 CFR 46.101. (b). For flow experiments, 
HUVECs were subcultured onto 30 mm glass cover slips pretreated with 1% w/v gelatin 
cross-linked with 0.5% glutaraldehyde [14]. The HUVECs were cultured at 37°C in a 
humidified 5% CO2 incubator. Confluent HUVEC monolayers were activated with IL-1β 
(1 ng/ml) for 4 h prior to use in flow assays. E-selectin expression on HUVEC was 
confirmed by immunofluorescence staining [15].       
3.2.4 Preparation of human blood 
  Venous blood was collected from adult donors into a citrate-containing syringe. 
Blood samples were collected according to protocols approved by the University of 
Michigan Internal Review Board and in line with the standards set by the Helsinki 
Declaration [16]. Red blood cells were sedimented from whole blood using a 6% dextran 
solution. Cell-free plasma (devoid of leukocytes and platelets) was obtained by 
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centrifugation of the leukocyte-platelet rich plasma layer at 500×g for 10 min and was kept 
at 37°C until used. Unless otherwise stated, reconstituted blood, i.e. isolated RBCs 
resuspended in cell-free plasma, at 30% hematocrit (% Hct) was used in flow assays.      
3.2.5 Experimental setup 
  A monolayer of activated HUVECs was vacuum-sealed to the microfluidic 
chamber such that the HUVEC monolayer formed the bottom plate of the rectangular flow 
channel. sLeA-coated spheres of a given size suspended in reconstituted blood at 5 time 105 
particles/ml, unless otherwise stated, were introduced into the flow channel from an inlet 
reservoir via a syringe pump. Adhesion assays were observed on an inverted microscope 
(Nikon TE 2000-S) fitted with a digital camera (Photometrics CoolSNAP EZ with a Sony 
CCD sensor). To account for any potential variation in fluxes along the chamber length as 
well as entrance effects, data was collected at a constant position midway from the entrance 
and exit of the chamber for all experiments.  
The wall shear rate (γw ; WSR) in the system was calculated from the adjustment of 
volumetric flow rate (Q) according to  
𝛾𝑤(𝑠
−1) =
6𝑄
𝑤ℎ2
 
where h is the channel height (28 µm or 43 µm) and w is the channel width (1000 µm). 
Adhesion assays were conducted with laminar flow through the channel at WSRs of 100 s-
1, 200 s-1 and 500 s-1, which are within the range of values reported for human microvessels 
in vivo [17-19]. Data is recorded as the number of particles that adhere to endothelial cells 
(ECs) after 5 min of flow divided by the area of view (0.152 mm2).  
 
(1) 
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Figure 3-1 Microchannel system. A) Top view of the microfluidic chamber showing the 
surrounding vacuum network system. Phase images of the microchannel (B) before and 
(C) during laminar blood flow.  Human endothelial cell monolayer is visible in (B). 
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Standard error bars are plotted and significances in data analyzed by one-way ANOVA 
with Tukey post-test (a value of p < 0.05 was considered statistically significant).   
3.2.6 Confocal imaging of particle localization to the chamber wall 
  A Leica Inverted SP5X Confocal Microscope (MIL, University of Michigan) was 
used to visualize the distribution of 0.5 and 2 µm spheres to the wall in reconstituted human 
blood flow at 30% Hct in a parallel plate flow chamber (PPFC) setup. Specifically, particle 
localization to a focal plane just above that of a resting 2 µm diameter sphere at the bottom 
of the PPFC was evaluated. Varied concentrations of particles, relative to a 1X 
concentration of 5 time 105 particles/ml, were mixed in blood, and then the mixture was 
induced into the flow chamber at a WSR of 200 s-1. The images of the focal plane were 
taken, and the fluorescence intensity for each image was calculated using Leica 
Microsystems LAS AF Lite Imaging Software. Fluorescence intensity was analyzed 
comparing to 1X concentration for each flow condition. 
3.3 Result and Discussion  
3.3.1 Effect of shear rate and channel height on binding dynamics of spheres in 
microchannels   
Vascular-targeted spheres with diameters ranging from 0.2 to 5 µm were allowed 
to interact with activated HUVEC monolayers in microfluidic channels from laminar 
reconstituted human blood flow at a fixed hematocrit (Hct) of 30%. As shown in Figure 3-
2, particle adhesion densities significantly increased with increasing spherical diameters 
from 0.5 to 2 µm for all laminar WSRs evaluated in the 43 and 28 µm height channels. The 
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adhesion densities of 0.2 and 0.5 µm spheres were not significantly different at all WSRs 
tested in both channels (p > 0.05; one-way ANOVA). The 5 µm spheres displayed either 
statistically the same or significantly lower adhesion density than the 2 µm spheres for all 
experimental conditions at 30% Hct in both channels with the exception of adhesion in the 
28 µm channel at 100 s-1.  In general, microspheres were found to be more efficient at 
binding from blood flow than the nanospheres evaluated, when fed at the same fixed 
concentration, likely because the latter exhibited minimal localization to the wall. It is well 
documented that in blood flow, RBCs congregate in the mid-line of flow leaving a RBC-
free layer (RBC-FL) near the vessel wall. Leukocytes, platelets and VTCs must localize to 
this RBC-FL in order to interact with the vessel wall. Several publications have reported 
that microspheres tend to disproportionately concentrate in the RBC-FL relative to 
midstream during blood flow in medium to large channels while spheres smaller than 1 µm 
do not exhibit such “near-wall excess” [6, 20].  Instead, a majority of the submicron to 
nanospheres in blood flow is retained within the RBC core, filling the void space between 
RBCs. The result presented in Figure 2 is the first report that nanospheres do not exhibit 
near-wall excess, or high margination, in human blood in channels on the order of human 
microvessels. A similar observation was previously reported by King et al. for the 
trajectory of fluorescent 500 nm particles in small venules of mouse cremaster tissue where 
it was shown that a high concentration of nanoparticles exist in the centerline of observed 
vessels while only a few nanospheres were found near the wall [21].  
To better understand particle adhesion trends in the context of adhesion kinetics, 
particle adhesion densities were normalized to the total number of spheres that perfused  
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Figure 3-2 Adhesion densities of sLeA-spheres to EC monolayer from laminar blood flow 
as a function of wall shear rate (WSR) in the (A) 43 µm and  (B) 28 µm height channels. 
Reconstituted blood at 30% Hct is used. * = p < 0.05 compare to binding at the immediate 
lower WSR and # = p < 0.05 compare to binding for the immediate smaller size at the same 
WSR via one-way ANOVA. n ≥ 3. 
 
64 
 
over the EC monolayer at 100 s-1 in the 28 µm channel via multiplying adhesion densities 
for all other conditions by the factor difference between the volumetric flow rates at these 
conditions and that of flow at 100 s-1 in the 28 µm channel. As shown in Figure 3-3, the 
normalized adhesion densities (i.e. adhesion efficiency) of nanospheres did not 
significantly change with increases in WSRs from 100 to 500 s-1 in both microchannels. 
For 2 µm spheres, the adhesion efficiency slightly decreased with the WSR increasing from 
100 to 200 s-1 in the 43 µm channel, but the adhesion efficiency for these spheres did not 
change with all increases in WSRs in the 28 µm channel. For 5 µm spheres, the adhesion 
efficiency significantly decreased for all WSR increases in both channels. Overall, the 
minimal decrease to no change in the adhesion efficiency of nanospheres and 2 µm spheres 
with WSR increases indicate that these spheres exist in a transport-limited adhesion regime 
(TLR) at the fixed sLeA density evaluated [6,22].  In this regime, particle adhesion density 
increases with increase in WSRs due to the increase in the number of particles, i.e. higher 
transport of particle, passing over the monolayer at higher WSRs for a fixed experimental 
time.  Conversely, 5 µm spheres exist in a reaction-limited regime (RLR), in which a high 
slip velocity exhibit by these spheres and higher disruptive force acting on them inhibit 
their adhesion at high WSRs; hence the decrease in adhesion density observed for the 5 µm 
spheres as the channel WSR increases. This existence of the 5 µm spheres in the RLR, i.e. 
poor adhesion kinetics, also explains their significantly lower adhesion relative to 2 µm 
spheres rather than their poor localization to the wall from RBC core. We have previously 
shown that sufficiently increasing the ligand site density on particles in the RLR enhances 
their adhesion kinetics and thus transition their adhesion into the TLR [6].  
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Figure 3-3 Normalized adhesion density of sLeA-spheres to EC monolayer from laminar 
blood flow as a function of wall shear rate (WSR) in the (A) 43 µm and  (B) 28 µm height 
channels. Reconstituted blood at 30% Hct is used. Data was normalized to the number of 
spheres passing over monolayer at 100 s-1 in the 28 µm height channel.  * = p < 0.05 
compare to binding of the same size at immediate lower WSR via one-way ANOVA. n ≥ 
3. 
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Overall, adhesion efficiency trended higher in the 28 µm channel relative to the 43 µm 
channel for all spheres though these increases were only significant for microspheres 
(Figure 3-3).  The size of the RBC-FL in humans has been reported to be between 2 – 10 
µm depending on the vessel size, WSR, and blood hematocrit, where RBC-FL typically 
decreases with decreasing vessel diameter at a fixed hematocrit [23-24]. Thus, a smaller 
RBC-FL, and hence a higher local concentration of spheres at a closer proximity to the 
wall, is anticipated in the 28 µm channel relative to the 43 µm channel.  A higher 
concentration of spheres at the wall would in turn lead to higher adhesion efficiency. The 
lack of a significant difference in the adhesion of nanospheres in the 28 µm channel relative 
to the 43 µm channel is again likely explained by their aforementioned minimal 
localization to the RBC-FL.  
3.3.2 Effect of blood hematocrit on sphere adhesion in microchannels 
 Blood Hct is an important factor that affects flow resistance in microvessels and 
the formation of the RBC-FL [25]. Thus, we investigated the impact of Hct on the binding 
of spheres in our microchannel system. Targeted spheres were introduced into channels at 
10%, 30%, and 50 % Hct at a fixed WSR of 200 s-1.  As shown in Figure 3-4A, the adhesion 
density of 2 µm spheres significantly increased as the blood Hct increased from 10% to 
50% in the 43 µm channel. This observation follows the expectation that a higher blood 
hematocrit in the flow channel would result in the shrinking of the RBC-FL, due to the 
enlargement of the RBC core, and hence a higher packing of small spheres closer to the 
targeted endothelial wall. The significantly steeper response to Hct observed for the 
adhesion of 2 µm spheres in the 43 µm channel relative to the nanospheres may be a result 
of the aforementioned minimal localization of nanospheres to the RBC-FL [6]. However, 
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the larger “RBC-FL-to-diameter” ratio exhibited by nanospheres that results in only modest 
packing of these spheres closer to the wall with changes in RBC-FL may also contribute to 
their shallower response relative to 2 µm spheres. The binding density of 5 µm spheres 
displayed a biphasic response to changes in Hct. The adhesion density of these spheres 
significantly increased when the Hct was increased from 10% to 30% but significantly 
decreased with a further increase to 50% Hct (Figure 3-4A). As aforementioned, the RBC-
FL with human blood flow in vivo is reported to range from 2 -12 µm.  Thus, at the 50% 
Hct evaluated in this study, it is likely that the RBC-FL is on the order of 5 µm or less, in 
which case 5 µm spheres in the microchannel likely experience “negative collisions” with 
RBCs in flow at this Hct to create an even higher disruptive force acting on their adhesion 
to the wall.  
In light of the observed decrease in the adhesion of 5 µm spheres at 50% relative to 
30% Hct, we sought to determine whether 2 µm spheres would still enjoy an almost linear 
increase in their adhesion with increase in Hct in the smaller height channel. As shown in 
Figure 3-4B, 2 µm spheres displayed the same biphasic adhesion pattern in the 28 µm 
channel as was observed for the 5 µm in the 43 µm channel with a peak adhesion occurring 
at 30% Hct. This is again consistent with the smaller RBC-FL layer anticipated in the 28 
µm channel at higher Hct. The adhesion of 5 µm consistently decreased with increasing 
Hct from 10 to 50% in the 28 µm channel. Overall, in both channels, microspheres 
displayed the best adhesion (~3-7 fold higher than that of nanospheres) at the 30% Hct that 
likely best represents average Hct in human microvessels – lower Hct values than the 
average systemic Hct (~45% in human) have been reported in microvessels due to the 
Fahraeus and plasma skimming effects [26].  
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Figure 3-4 Adhesion density of particle as a function of blood hematocrit in the (A) 43 µm 
and (B) 28 µm height channels with laminar flow at a WSR of 200 s-1. n ≥ 3 and p < 0.05. 
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3.3.3 Effect of particle concentration on sphere adhesion in microchannels 
 Previous publications have argued that, owing to their much smaller size, 
nanoparticles can be injected into the bloodstream at a higher concentration than 
microspheres and that higher injection concentration would directly translate to their 
enhanced margination to the vascular wall. Thus, we evaluated the adhesion of all spheres 
in blood flowing at 200 s-1 in the 28 µm channel at 30% Hct (similar condition to Figure 
3-2B) with a particle concentration of 2.5 × 106  spheres/ml – 5 times higher concentration 
than the one used in previous assays. The 28 µm channel is used for this analysis as it is 
expected to present the most dramatic effect of particle concentration, if present, due to its 
smaller RBC-FL relative to the 43 µm channel. As shown in Figure 3-5A, microsphere 
adhesion at the 5 times higher particle concentration was ~4.81 to 5.29 times higher than 
the adhesion reported in Figure 3-2B, i.e. microspheres maintained similar or slightly better 
margination at the higher particle concentration relative to the lower concentration. 
Conversely, the adhesion of nanospheres at the 5 times higher feed concentration was only 
~1.96 – 2.62 times higher relative to their adhesion at the baseline particle concentration. 
This observed non-linear correlation between concentration and adhesion for nanospheres 
further supports our assertion that nanospheres do not effectively localize to the RBC-FL 
in bulk blood flow relative to small microspheres. More importantly, a disproportionately 
higher nanosphere concentration compared to small microspheres would likely be required 
to deliver similar particle numbers or volume density at the vascular wall, which would be 
problematic for delivery of highly potent drugs, as the majority of the nanospheres would 
remain in systemic circulation.  While it is possible that the inherent equilibrium position 
of nanoparticles in the RBC-FL that places them sufficiently far from the wall such that 
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their adhesion is a weak function of concentration can explain the results shown in Figure 
3-5A, a control adhesion experiment with buffer flow show 500 nm particles responding 
to a 5X increase in concentration in a nearly linear manner and with their response 
matching that of 2 µm spheres (Figure 3-5B). Furthermore, an observation of the RBC-FL 
for a 30% Hct blood flow in a PPFC at 200 s-1 via confocal microscopy visibly shows 2 
µm spheres localizing to the wall at a significantly higher concentration than 500 nm 
spheres at the same high 5X particle concentration in blood (Figure 3-6). An analysis of 
the effect of particle concentration in flow on their localization wall via measurement of 
fluorescent intensity of confocal images also show result similar to Figure 3-5A, where the 
500 nm spheres returned a ~2.x fold increase in localization for a 5 fold increase in particle 
blood concentration while the response was 1:1 for the 2 µm spheres.  
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Figure 3-5 The ratio of particle adhesion density for the 2.5 x 106 relative to the 0.5 x 106 
particles/ml feed concentrations in (A) reconstituted blood flow at 30%Hct, and in (B) 
Phosphate buffered saline at 200 s- 1 in the 28 µm height channel. n ≥ 3. 
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Figure 3-6 The confocal microscopy images of (A) 0.5 µm spheres and (B) 2 µm spheres 
in 30% Hct blood flow at 200 s-1 with the same high 5X particle concentration (2.5 x 106 
particles/ml). The images were taken at the same plane on bottom surface of the chamber.    
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In conclusion, we evaluated the adhesion of sLeA-coated nano- and microspheres 
to inflamed human endothelial cells from physiological human blood flow in microfluidic 
channels with dimensions on the order of human microvessels. Microspheres, particularly 
2 µm spheres, were found to outperform nanospheres in all hemodynamic conditions 
evaluated due to the poor ability of the latter to localize to the blood vessel wall from blood 
flow. The presented work represented the first evidence that nanospheres may not exhibit 
significant “near wall excess” in microvessels.  This finding may be of importance for the 
design of vascular-targeted carriers for imaging and treatment of cancer.  While the 
majority of targeted delivery systems are designed to target capillaries in tumors, their 
potential ineffective localization in tumor arterioles and venules is likely consequential 
since (1) the bulk of blood flow that enters a capillary branching off an arteriole is skimmed 
from the wall region on the branch side (i.e. plasma skimming effect); therefore, low 
numbers of nanospheres would enter the capillaries, and (2) in some cases, tumor 
vasculature has been reported to exhibit a high percentage of arteriolar-to-venular shunt 
[27]. Thus, there remains a critical need for research to identify ways in which targeted 
nanosphere delivery to the vascular wall can be enhanced. Nanospheres will likely remain 
attractive for use as drug carriers due to the ease of their fabrication, their tendency to resist 
systemic clearance, and their capacity to undergo endocytosis and transcytosis upon 
contact with the endothelium.  One promising avenue may be the use of micrometer-sized 
carriers to deliver encapsulated nanospheres to the vascular wall. However, this would 
require a design strategy that tightly balances the timing of microcarrier degradation and, 
hence, the release of nanospheres with the high rate of systemic clearance that tends to 
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exist for microspheres in the size range shown in this work. Our ongoing work is exploring 
this and other possibilities. 
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CHAPTER 4 
VARIATION IN HEMORHEOLOGY BETWEEN HUMAN AND 
ANIMAL BLOOD AND THE EFFECT OF BINDING EFFICACY OF 
VASCULAR-TARGETED DRUG  
Abstract 
Several animal models are extensively used in experimental research as a mean to 
understand human diseases and evaluate new therapy. This includes the fields of vascular-
targeted imaging and drug delivery. Despite the comparable in vivo physiological 
environment between most animal models and human, there are still many variations that 
can significantly alter the experimental results obtained with animal models relative to 
human system, especially, blood composition and physical properties of blood cells. In the 
vascular-targeted drug delivery field the effects of the variation in hemorheology, 
hemodynamics and the structure of vasculature between common animal models and 
human has typically been overlooked. This study aims to investigate the role of 
hemorheology of various animal models and human on dictating the binding efficiency of 
spherical vascular-targeted drug carriers (VTCs) at the wall in physiological blood flows. 
Specifically, the adhesion of sLeA-coated particles, 0.2, 0.5, 2 and 5 µm, to inflamed 
endothelial cells monolayers were conducted via a parallel plate flow chamber assay 
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(PPFC). Particle binding was observed in RBCs-in-buffer (washed red blood cells (RBCs) 
suspended in saline) and whole blood, in laminar, pulsatile and recirculating flow. Our 
results suggest that RBCs size compared to the carrier size dictate the particle binding in 
blood flow. The cell free layer (CFL) width and formation of RBCs core may vary with 
RBC size and rheology, at fixed hematocrit (RBC volume fraction in blood), and this 
variation can affect the binding density/trend of particles since the proper ratio of particle 
size to CFL width is necessary for the optimal particle binding. Additionally, the presence 
of white blood cells also appears to affect the trend of particle adhesion in different animal 
species. Overall, this work sheds light on the potential deviation of results investigated in 
vivo by utilizing animal models from what might be the expected outcome in human.  
 
 
 
 
 
 
 
 
 
 
 
 
* Content of this chapter is being prepared for publication.  
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4.1 Introduction 
To date, vascular-targeted drug delivery remains of tremendous interest for use as 
an alternative for treating several diseases. To this end, several works have focused on 
characterizing the capacity for vascular-targeted drug carriers (VTCs) to markedly adhere 
to a targeted location either via various in vitro static and flow assays ranging in complexity 
from simple buffer to blood flows, e.g. [1-4], or in various animal models of human 
diseases, e.g. [5-8]. In vivo assays are preferentially used due to the many challenges 
associated with recreating the complexity of the human in vivo cellular and biochemical 
environment with in vitro assays. Animals prominently used in drug delivery research 
include rodents, rabbits, pigs, dogs and monkeys [9-12]. While the pathology of many 
human diseases can be faithfully represented in these animals at the cellular, and in some 
cases organ levels, many of them have differences in their physiology relative to human 
(e.g. vessel size and hemodynamics) that may limit the extrapolation of the generated data 
to human physiology [13]. This includes differences in shear rates, plasma protein 
compositions -that affect blood viscosity and red blood cell (RBC) aggregation, and blood 
cell properties (i.e. size, shape and deformability). The discrepancy in the physiology 
between laboratory animals and human is likely most critical in the evaluation of 
particulate delivery systems where the identified differences in hemorheology and 
hemodynamics impact the distribution and performance of these systems/therapy. Indeed, 
we recently reported that human RBCs have a significant influence on the binding 
efficiency of nano- and micro-particles targeted for binding to the inflamed endothelial 
cells (ECs) under physiological blood flow via in vitro flow assays [2, 8, 14-16]. We 
showed that small microspheres and micro-rods exhibit a high capacity to marginate 
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(localize and adhere) to inflamed human ECs at the wall from steady and disturbed human 
blood flow, while nanospheres and nanorods exhibit limited margination. The observed 
size effect on the margination of particles is due to the well-documented preferential 
migration of RBCs away from the wall and alignment at the center of the flow that creates 
a RBC-free layer (CFL) near the wall. This inward movement of RBCs causes 
microparticles (as well as micrometer sized leukocytes and platelets) in blood flow to 
concentrate in the CFL via exclusion, enhancing their collision and contact with the 
vascular wall. A significant fraction of nanoparticles in bulk blood flow, however, are 
entrapped within the RBC core resulting in their low margination - i.e. they exhibit a low 
capacity to localize to the CFL [8]. The CFL width has been reported to vary from 2.5 - 
7µm in humans and some small animals depending on the hydrodynamic shear rate of flow, 
vessel size, the volume fraction of RBC or percent blood hematocrit (% Hct), and the 
aggregability and deformability of the RBCs [1, 17-20]. Therefore, any subtle differences 
in the physical properties of RBCs between various animal models that possibly result in 
their differential lateral migration, and hence the formation of CFL of various sizes, may 
eventually lead to variations in particle behavior and margination in different animal 
models.  
Variations in RBCs and blood characteristics between human and other common 
laboratory animals prominent in drug delivery research have been reported, including for 
mice, pigs, rabbits, dogs and monkeys. For example, the volume, and aggregability of 
RBCs in mouse blood, a common animal species used for vascular-targeting research, are 
significantly smaller/lower than in humans [13, 21]. Yet, to date, very limited works have 
investigated the impact of these variations in hemorheology between animal models and 
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human on the hemodynamics of particulate carrier systems as it relates to their margination 
to the vascular wall. Thus, this study aims to elucidate the role of RBC dimension in 
dictating the binding efficiency of spherical particles of various sizes in blood flow of 
different patterns. Specifically, we evaluated the adhesion of inflammation-targeted 
polystyrene spheres in a parallel plate flow chamber (PPFC) to inflamed endothelial cells 
from physiological flow of RBC-in-buffer (washed RBCs suspended in saline at fixed 40 
% Hct) from different animals species and human, rabbit , pig and mouse whole blood. 
Overall, our results show that the capacity of VTCs to marginate to the vascular wall is 
significantly influenced by blood flow types and most importantly, RBC size. 
4.2 Methods 
4.2.1 Preparation of vascular-targeted spheres 
The preparation of VCTs in this chapter is described in detail in chapter 3.  
4.2.2 Preparation of human endothelial cells (ECs) monolayer 
The preparation of human umbilical vein endothelial cells (HUVECs) in this 
chapter is described in detail in chapter 3. 
4.2.3 Preparation of RBC-in-buffer and whole blood (WB) 
Human blood was collected from healthy adult donors via venipuncture into a 
syringe containing citrate anticoagulant (acetate-citrate-dextrose, ACD) same procedures 
as described in chapter 3.  
To prepare human RBCs suspended in saline, a 6% wt dextran-250 solution (1.4 
ml/10 mL of blood) was added into anti-coagulated whole blood. This mixture was kept at 
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room temperature for approximately 2 hr to allow RBCs to sediment separating from the 
leukocyte-platelet rich plasma layer at the top. RBCs collected from the bottom layer were 
washed with Dulbecco's phosphate buffered saline (DPBS) three times via centrifugation 
at 1000 g for 30 min, then the RBC pellet was collected and resuspended in DPBS+ with 
1% BSA (flow buffer) to achieve a 40% Hct, i.e. volume fraction of RBCs to plasma [2]. 
To prepare animal RBCs-in-buffer, isolated pig, cow and rabbit RBCs were obtained 
commercially (Lampire Biological Lab, Pipersville, PA). For the murine RBC-in-buffer 
assays, mouse whole blood was collected from surplus mice generously provided by the 
breeding colony of Unit of Laboratory Animal Medicine (ULAM) according to a protocol 
approved by ULAM and University Committee on Use and Care of Animals (UCUCA) at 
the University of Michigan. Briefly, mouse blood was drawn from anaesthetized mice by 
a cardiac puncture into a syringe containing heparin as an anticoagulant. The obtained 
animal whole blood was then centrifuged at 1000 g for 30 min to collect RBCs. Isolated 
RBCs were then washed in DPBS to minimize the excess anticoagulant and/or plasma 
constituents and were spun down at 1000 g for 30 mins. The RBCs for all animals were 
then resuspended in DPBS+ with 1% BSA at 40% Hct to yield RBCs-in-buffer.  
For whole blood experiments, mouse and rabbit whole blood containing heparin 
and human whole blood containing ACD were stored at 4°C overnight before use.  
4.2.4 Flow adhesion experimental set up 
A parallel plate flow chamber (PPFC) equipped with a straight (for laminar and 
pulsatile flow) or vertical step (for recirculating flow) gaskets forming the flow channel 
(GlycoTech, Gaithersburg, MD) were used for in vitro flow adhesion assays. Flow assays 
were constructed as described in a previous publication with minor modifications [2]. 
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(1) 
Briefly, a single straight gasket or a layered step channel was placed over an activated 
HUVEC monolayer cultured on a glass coverslip and vacuum-sealed to the flow deck to 
form the bottom adhesion substrate of the flow chamber assay. Vascular-targeted spheres 
of a given size suspended in buffer or blood at a fixed concentration of 5 ×105 spheres/ml 
were introduced into the flow channel from an inlet reservoir via a programmable syringe 
pump (KD Scientific, Holliston, MA).  
For laminar flow assays, the wall shear rate (WSR; γw ), was computed using the 
approximation (chapter 3) 
𝛾𝑤(𝑠
−1) =
6𝑄
𝑤ℎ2
 
using the volumetric flow rate (Q) through the channel (mL/min), where h is the channel 
height (254 µm, unless otherwise noted) and w is the channel width (1 cm unless otherwise 
noted).  
For pulsatile flow, a programmable syringe pump was used to induce two profiles 
of pulsatile flow in the horizontal PPFC as previously described [14]. For the first pulsatile 
profile (Profile I), blood was pulsed about 10 s-1 with a net flow in the forward direction. 
Specifically, the syringe pump was set to run continuous loops with 14 s of forward flow 
followed by 7 s of backward flow for at total experimental time of 5 minutes. Maximum Q 
was set at 3.225 mL/min (500 s-1) or 6.45 mL/min (1000 s-1) and WSR(t) computed from 
Q(t) according to equation (1). 
For the second pulsatile profile (profile II), blood was pulsed only in the forward 
direction from a low WSR of 120 s-1 for 4 seconds to a high shear of 1200 s-1 for 2 seconds 
with the total flow time set at 5 min.  
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Recirculating flow was generated via a vertical-step gasket (VSFC) [24] that 
formed entrance and main channel heights of 127µm and 508 µm (0.5 cm width), 
respectively, as previously described [14]. The sudden expansion at the step generates 
recirculation in flow where a two-dimensional flow with a parallel (Vx) and a normal flow 
velocity (Vz) with respect to the channel bottom wall is established. The recirculation 
vortex extends from the step to a reattachment point where Vx=0 and only a negative Vz 
(pointing toward the bottom wall) is present. Beyond the reattachment, flow moves 
forward, and a laminar profile is reestablished at far downstream. The flow rate through 
the VSFC was set such that a laminar WSR of 200 s-1 was achieved in the main chamber 
for 5 min.  
Flow adhesion assays were observed on a Nikon TE 2000-S inverted microscope 
fitted with a digital camera (Photometrics CoolSNAP EZ with a Sony CCD sensor). Digital 
recording of experiments was via Metamorph analysis software. All adhesion experiments 
were conducted at 37°C and each cell monolayer was used once.  
4.2.5 RBC volume measurement 
To determine the average RBC volume for all animal and human blood, 15 ml of 
whole blood was spun down at high-speed, 1000 rpm, for 30 mins, then the WBC layer 
and plasma were removed. 1 ml of RBCs, from the bottom part of RBC layer (assuming 
RBCs were completely packed), were collected and diluted in DPBS buffer (2000X, 5000X 
and 10,000X). RBCs concentrations were counted by hemocytometer. RBC volumes are 
calculated based on RBCs/volume. All processes were repeated 3 times. 
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4.2.6 Data analysis 
Particle binding density (#/mm2) in laminar and pulsatile flow is obtained by 
manual count of the number of particles bound on the cell monolayer after 5 min of flow 
and dividing this number by the area of the field of view (20x magnification, A = 0.152 
mm2, unless otherwise stated). For recirculating flow experiments, the number of particles 
bound downstream of the step channel was counted in 100 µm intervals (area of strip = 
0.034 mm2), as previously described [14]. For adhesion at far downstream where laminar 
flow is re-established [25], the adherent particles were counted at a distance of 5000 µm 
from the step. Each data point represents an average of at least three experiments and 
includes at least five fields of view per experiment. Standard error bars were plotted unless 
otherwise stated. Differences in adhesion levels were analyzed using a student t test and 
one-way ANOVA with Tukey post-test. A value of p<0.01 was considered statistically 
significant. To estimate a range of optimal particle size for each flow condition, we used a 
Monte Carlo method that incorporated the variability in particle size with the binding data 
[15].  
4.3 Results 
To study the effect of red blood cell (RBC) size (diameter and volume) on the 
localization and adhesion of VTCs to the vessel wall, sLe A-coated spherical particles, 0.2, 
0.5, 2 and 5.7 µm diameter, were observed from their binding to inflamed endothelial cells 
in laminar flow of human, pig, mouse and rabbit RBCs-in-buffer (RBC in buffer at 40% 
Hct) or whole blood in a PPFC. The average diameter, volume, and the ratio of RBC 
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volume to diameter (VDR) of the different animal RBCs used are summarized in Table1 
[26].  
 
 
 
Species Diameter (D) Volume (V) VDR 
Human 7.3 95 13.88 
Rabbit 6.1 76 13.35 
Pig 5.81 61 11.17 
Mouse 5.8 41 7.55 
 
4.3.1 Effect of RBC size on particle adhesion in laminar flow  
Figure 4-1 shows the average binding densities for sLeA-particles observed in 
laminar RBCs-in-buffer flows at a wall shear rate (WSR) of 500 s-1. Overall, the adhesion 
density of microspheres at this shear rate was significantly higher than the adhesion of 
nanospheres. We should note that for all but the 2 µm particles, adhesion in rabbit and pig’s 
RBCs flow were not significantly different (Table 4-2). When focused on the binding of 
spheres of a giving size, the adhesion of the 2 µm spheres was found to significantly 
increase as the RBCs-in-buffer changed from mouse to pig to rabbit following the order of 
increase in RBC volume (from 41 to 61 to 76 µm3 , respectively). Nevertheless, the 
adhesion of the 2 µm spheres in human RBCs-in-buffer flow was significantly lower than 
the density observed in both rabbit and pig RBCs flows despite the volume of the human 
RBC, 95 µm, being significantly larger than RBC volume in these animals. However, the 
binding density of 5 µm particles decreased significantly relative to 2 µm particles in 
mouse, pig and rabbit RBCs-in-buffer flow while binding increased in the human model.  
This observation suggest a trend in particle binding with RBC volume, albeit non-linear 
Table 4-1: Red blood cell average dimensions of human and different animal 
species 
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one. To further probe how RBC geometry in the different animals affect the flow adhesion 
of particles of different sizes, we plotted the adhesion density data shown in Figure 4-1A 
as a function of RBC diameter, RBC volume, and reduced volume (defined as the ratio of 
the averaged RBC volume, to the volume of a sphere with the same diameter as the RBC), 
and we found no appreciable trend for particle binding. However, as shown in Figure 4-
1B, particle adhesion seems to have a linear relation to the RBC volume to diameter ratio 
(VDR), except again for larger particles with human RBCs. This particle binding trend in 
RBCs-in-buffer flows relative to the RBC VDR is similar to the trend observed for particle 
binding as a function of RBC volume for the different particle sizes (in Figure 4-1A the 
bars are plotted in the order of increase volume left to right). This would suggest that RBC 
volume is more important than RBC diameter in the dynamic interactions of RBC and 
particles in blood flow. However, the lack of a general trend in the effect of RBC volume 
on binding for all particles sizes, and previous studies where we observed that binding 
density of particles larger than human RBCs drops drastically (e.g. 10 µm spheres [15]), 
prompted us to look at whether a correlation exist between particle and RBC size. Figure 
4-1C shows the plot of particle binding density as a function of the ratio of particle diameter 
to RBC diameter, defined as ϕ, where we see a significant correlation. This ratio takes into 
account not only the size of the particle, but also how it compares to the size of the RBC. 
There was no clear fit of the data with RBC volume, diameter, reduced volume or VDR. 
However, when we normalized the particle sizes to the RBC size, we could see a quadratic 
relation similar to what was observed in [15] for particle binding in human RBC flow as a 
function of particle size. Thus, we estimated an optimal ϕ range using a Monte Carlo 
method that incorporates the variability in particles sizes with the binding data using 
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quadratic fit, as done in [15], which gave surprising results. For example, the optimal range 
for ϕ in figure 4-1 translates to the range 3.97< dopt <4.55 µm for human RBCs in 40% Hct, 
with an average R2 of 0.94, where dopt is the optimal particle diameter for the given flow. 
This agrees with the range of 3.8< dopt <4.4 µm in 45% Hct given in [15] for human RBC 
in plasma, as the optimal size decreases with increased hematocrit. For completeness, we 
looked at the relation between particle binding and the ratio of particle volume to RBC 
volume, which didn’t yield a good fit.  
To see if this size effect was the same when all components of blood were present, 
we ran the experiments with mouse, rabbit, pig and human whole blood flow at 500 s-1. No 
binding was found for pig’s whole blood, which may be linked to interference of proteins 
or complement in pig blood plasma with particle binding [4]. There was a general decrease 
in particle binding density in whole blood flow for the rest of the species for microparticles 
elative to adhesion in RBCs-in-buffer flows, being more pronounced for rabbit. Although 
a quadratic relation is still observed between ϕ and density binding, an R2 of 0.75 suggests 
that non-geometric characteristics of blood, such as the proteins in plasma or number and 
size of white blood cells (WBCs), play a significant role in particle binding. For example, 
around 80% of WBCs in rabbits are lymphocytes, which are significantly smaller than a 
rabbit RBC, whereas the majority of human WBCs are neutrophils, which are almost twice 
the size of an RBC. This suggests that the large size of neutrophils in humans might aid the 
migration of particles to the wall. 
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Figure 4-1 Adhesion of sLeA-particles in human, pig, mouse and rabbit laminar RBCs-in-
buffer flow, 40% Hct at 500 s-1 WSR (a) histogram, (b) vs VDR and (c) ratio of particle 
diameter to RBC diameter, 0.57< ϕopt <0.65, (R2 = 0.94). 
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Figure 4-2 Adhesion of sLeA-particles in human, mouse and rabbit laminar RBCs-in-
buffer, 40% Hct, and whole blood flow at WSR 500 s-1: (a) histogram, (b) particle to RBC 
diameter ratio (RBCs-in-buffer 0.54< ϕopt <0.62, R2=0.93; Whole Blood 0.46< ϕopt < 0.53, 
R2 = 0.75). 
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4.3.2 Effect of RBC size on particle adhesion in pulsatile flow 
To identify if particle binding trend in laminar RBC-in-buffer and blood flow can 
be generalized for the different flow patterns in circulation, we studied the adhesion of 
particles in pulsatile flow. First we used pulsatile profile I (described in method section), 
with mouse, pig, rabbit and human cells. In general, the adhesion levels were lower than in 
laminar flow due to the smaller volume of blood, thus number of particles that passed 
through the channel owing to the cycling between low and high shear rate for a fixed 
experimental time (figure 4-3A). For 0.5 and 2 µm particles, the difference between pig, 
rabbit and human RBCs-in-buffer flow adhesion levels was not significant (p>.01, see 
Table 4-2). All the animals followed a quadratic pattern with respect to the ratio ϕ, and no 
clear relation was found with volume, diameter, reduced volume or VDR as with laminar 
flow. The whole blood experiments were ran only for human, mouse and rabbit as the 
laminar flow experiments showed no adhesion in pig’s whole blood. There was only a 
small decrease in adhesion in whole blood experiments compared to RBCs-in-buffer flow 
trials. This is likely due to   the changes in shear force during flow that provides favorable 
conditions to overcome WBC competition. The quadratic fit of adhesion density vs ϕ 
yielded an R2=0.78 for RBCs-in-buffer flow and R2 = 0.81 for whole blood flow. The 
optimum particle size was found to be in the range 3.40 < dopt < 4.92 µm for humans, 2.84 
< dopt < 3.28 µm for rabbits and 2.70 < dopt <3.12 µm for mice in RBCs-in-buffer flow. In 
the case of whole blood the ranges are 3.28 < dopt < 3.80 µm for humans, 2.61 < dopt < 3.02 
µm for rabbits and 2.75 < dopt < 3.17µm for mice. 
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Figure 4-3 Adhesion of sLeA-particles in human, mouse, pig and rabbit pulsatile RBCs-
in-buffer flow at 40% Hct, 10-500 s-1 WSR: (a) histogram, (b) plot vs VDR, (c) particle 
to RBC ratio (0.47< ϕopt <0.54, R2 = 0.78). 
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Figure 4-4 Adhesion of sLeA-particles in human and mouse pulsatile RBCs-in-buffer and 
whole blood flow at 10-500 s-1 WSR: (top) histogram, (bottom) particle to RBC ratio 
(RBCs-in-buffer 0.45< ϕopt < 0.52, R2=0.78; Whole Blood 0.45< ϕopt < 0.52, R2 = 0.81). 
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To test further the effect of pulsatile flow, the WSR was fluctuated between 120 s-
1 and 1200 s-1 using human and mouse RBCs-in-buffer flow and whole blood flow (figure 
4-5). For both flows, the adhesion levels were higher than at the slower flow, which is 
somehow expected as the number of particles per experiment increases with WSR. The 
trend versus ϕ again yields a quadratic fit with an R2=0.80 for RBCs-in-buffer flow, and 
R2= 0.91 for whole blood. The optimal ranges for particle size decreased to 3.36 < dopt < 
3.87 µm for humans and 2.67 < dopt < 3.07 µm for mice in both RBCs-in-buffer and 
whole blood flow.  
Finally human and mouse whole blood flow was tested at a 50 - 500 s-1 
fluctuating WSR (figure 6). The trend within each species was the same, with mouse 
peaking in the range of [2.38, 2.78] and human in [2.99, 3.50]. For 2 µm particles the 
adhesion density was higher for mouse than human, which didn't occur in any other case. 
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Figure 4-5 Adhesion of sLeA-particles in human and mouse in pulsatile RBCs-in-buffer 
and whole blood flow at 40% Hct,120-1200 s-1 WSR: (top) histogram, (bottom) particle 
to RBC ratio (RBCs-in-buffer 0.46 < ϕopt < 0.53,  R2 = 0.80; Whole Blood 0.46 < ϕopt < 
0.53,  R2 =0.91). 
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4.3.3 Effect of RBC size on particle adhesion in recirculating flow 
Recirculating flow was achieved by fitting a step at the entrance of the PPFC 
yielding a swirling effect. The flow was pumped at a flow rate Q=2.58 ml/min to achieve 
a WSR of 200 s-1 at the point of flow reattachment. We measured the density every 100 
µm after the step, and downstream at 5000 µm where the flow stabilizes and behaves as 
laminar flow. Once again, human, mouse, rabbit and pig's RBCs-in-buffer were tested. In 
figure 4-6 adhesion densities are plot by size. The 0.2 and 0.5 µm particle adhesion levels 
are still very low, and no pattern can be discerned. For 2 µm particles, the adhesion levels 
increased, with rabbit doing better than the other species, while human did best for 5 µm 
particles, as in the other types of flow. The adhesion peaked around 500 µm from the step 
for the microparticles. At this location, human, mouse and pig adhesion levels increased 
with particle size, while rabbit showed a decrease from 2 µm to 5 µm particles (figure 4-
7). Although there is still a quadratic pattern with respect to ϕ, the fit was poor with an 
R2=0.81.  
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Figure 4-6 Adhesion of sLeA-particles in human, mouse, rabbit and pig recirculating 
RBCs-in-buffer flow at 40% Hct, 200 s-1. 
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Figure 4-7 Adhesion of sLeA-particles in human, mouse, rabbit and pig recirculating 
RBCs-in-buffer flow 40% Hct, 500 µm from step: (a) histogram, (b) particle to RBC 
diameter ratio (0.74 < ϕopt < 0.85,  R2 = 0.81) . 
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Figure 4-8 Adhesion of sLeA-particles in human, mouse and rabbit recirculating whole 
blood flow at 40% Hct, 200 s-1. 
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Figure 4-9 Adhesion of sLeA-particles downstream in human and mouse recirculating flow 
at 40% Hct, 200 s-1:(a) histogram, (b) adhesion vs particle to RBC diameter ratio (ϕ), (at 
500 µm RBCs-in-buffer 0.65 < ϕopt < 0.74,  R2 = 0.85, Whole Blood 0.53 < ϕopt < 0.61, R2 
= 0.67; Downstream µm RBCs-in-buffer 0.49 < ϕopt < 0.57, R2 = 0.87, Whole Blood 0.44 
< ϕopt <0.51,  R2 = 0.67 ). 
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The same analysis was made using whole blood in recirculating flow for mouse, 
rabbit and human (figure 4-8). Rabbit whole blood has low levels of binding across the 
board, indicating a WBC effect. Mouse whole blood did particularly well for medium to 
small particles; 200 nm 500 nm and 2 µm spheres. Particle binding in human whole blood 
increased along with particle size. Within each particle size, adhesion in human blood 
peaked around 500 µm from the step (figure 4-8) and declined along far downstream, where 
it almost tripled decrease of particle binding in downstream to the peak (500 µm from the 
step)(figure 4-9). It should be noticed that binding in whole blood flow was higher than in 
RBCs-in-buffer flow both at 500 µm from the step and downstream (figure 4-9), but the 
optimal range for particle size in human decreased from 5.40 < dopt < 6.21 µm in RBCs-in-
buffer flow, to 4.74 < dopt < 5.40 µm in whole blood.  
4.4 Discussion 
Due to the many advantages gained from utilizing imaging modalities and vascular-
targeted drug delivery in the early diagnosis and treatment of diseases, several research 
works have been focused on the design and engineering of the optimal vascular-targeted 
carriers used to localize contrast and/or therapeutic agents to a target site in several human 
diseases, including cancer and cardiovascular diseases. To ensure the in vivo functionality 
of designed delivery system, most researchers utilize animal models of human diseases, 
and this primarily represents the core of preclinical research prior to advancement to 
clinical testing. Mouse, rat, rabbit, pig, dog and monkey models are extensively used for 
testing in the preclinical research relating to vascular-targeting [9-12], despite the 
significant differences in blood rheology, hemodynamics and the vasculature structure of 
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these animals relative to human [13, 21, 27, 28]. Though the potential correlation and the 
suggested scaling factor of a particular animal to human, respective to their differences in 
macroscopic scale (e.g. shear stress) are available [27, 28], limited works have studied the 
potential implications of the variations in microscopic scale, including different size of 
blood cells and plasma constituents, on the efficiency of vascular-targeted drug delivery 
relative to human physiology. The few works that exist have primarily focused on platelet 
adhesion in high shear laminar flow. In [29], they found differences in platelet adhesion in 
whole blood flow of different mammalian species via controlled in vitro assays. Aarts et 
al. observed via flow assays with RBCs of various animals that the adhesion of human 
platelet increased with increasing RBC sizes [30].  Due to the significant influence of RBCs 
and other blood cells on particle margination in blood flow as thoroughly described in [14-
16], it is likely that the distinct hemorheology that exists in animal models relative to 
humans, particularly the difference of red blood cell (RBC) size, can result in the 
differential pattern of targeted carrier localization and adhesion (margination) of particles 
of various sizes to the vascular wall.  Herein, the adhesion of sLeA coated particles, 0.2, 
0.5, 2 and 5 µm in diameter, to the inflamed endothelial cells in flow of human, pig, mouse 
and rabbit RBCs-in-buffer (40% Hct RBCs suspended in saline) and whole blood was 
observed in vitro via parallel plate flow chamber (PPFC) assays with physiological shear 
conditions. Overall, the presented results showed that the binding efficiency of particles 
varies with the dimension of RBCs corresponding to different animal models, flow types 
and blood constituents.  
In buffer flow, we know that the discrepancies in particle binding density are due 
to geometrical properties of their RBCs as there are no other variables present. We showed 
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that the particle diameter to RBC diameter ratio, ϕ, gives us a good statistical estimate of 
the effect. Nevertheless, to have a better fit, we would need to be able to vary all length 
variables in the experiments accordingly, for example, channel height, WSR and even 
RBCs rigidity, which is not feasible in our in vitro experimental setup. Thus, for example, 
since these adhesion experiments were observed in RBCs-in-buffer at fixed RBC volume 
fraction in the same channel size (at 40% Hct, which closely represents the in vivo 
conditions in the animals evaluated), a larger number of RBCs with smaller volume, e.g. 
mouse RBCs, relative to human, would be required to yield the same hematocrit in the 
same blood volume. Without adjusting the channel height and WSR for each species, 
formation of RBCs at center of the flow is different depended on the size and volume of 
RBCs, which would affect the size of the CFL and, therefore, of the particle margination. 
For this same reason, in whole blood experiments, the fit is not accurate due to the variety 
of the different blood components on each species, which in turn affects the margination 
in a non-linear way. Another factor to keep in mind is RBC deformability, as it is known 
to strongly affect the alignment of RBCs under shear flow, i.e. less rigid RBCs tend to 
migrate to the center of flow while more rigid RBCs, less susceptible to the shear flow, are 
likely to stay adjacent to the wall [31]. Even though mouse and pig's RBC average diameter 
is similar, and thus their corresponding ratios ϕ, there are two significant differences: 
firstly, mouse RBCs are more deformable than pig RBCs [32]; secondly, pig's average 
RBCs volume is larger than mouse's RBCs average volume (Table 4-1). These two factors 
would account for the difference in binding in both species, although there is no discernable 
pattern in adhesion density relating particle size and either deformability or volume. For 
instance, in laminar flow (figure 4-1), pig's adhesion is lower for 0.2 µm particles, but 
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higher for all other sizes, while in pulsatile flow (figure 4-3) pig's adhesion is lower than 
mouse's adhesion for nanoparticles, and higher for microparticles.  
In whole blood flow, it is clear that the difference in adhesion levels depend 
strongly on the animal species, and therefore, on the specific blood constituents. For 
instance, in pig's model, there was no binding in any of the flow profiles, which is likely 
due to pig's protein composition that result in surface absorbed protein hindering the 
targeting ligands' ability to adhere to the wall [4]. For the other three species, human, mouse 
and rabbit, the RBCs diameter to particle diameter ration ϕ, still yields a good fit, although 
there is another effect on mouse and rabbit whole blood. As this effect is not as pronounced 
as in pig, we looked into the composition of mouse’s and rabbit's blood, specifically white 
blood cells. The majority of mouse’s and rabbit's white blood cells are lymphocytes, 
smaller than the RBCs, while humans have more neutrophils which is twice larger than 
human RBCs.  Our previous study presents that human WBCs interfered with microparticle 
adhesion on EC [15], so the smaller size and concentration of WBCs may be other factors 
to dictate particle adhesion which still requires further study to confirm.   
Overall, our findings address many important factors that help optimize the 
margination of micro- and nano-particles in different species. First of all, it showed the 
relevance of the relative size of the particle to the RBC, so that in vivo assays in animals 
have to be adjusted before applying them to humans. Although the effect of hematocrit was 
not investigated for the different animal species, this is not expected to affect the trend as 
we had previously showed that the trend does not change in human [15]. Second of all, 
although it didn’t fully elucidate the role of plasma and other cells’ components, it clearly 
showed that these have an effect in the binding efficiency of vascular-targeted carriers, thus 
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raising the awareness of potential deviation of results investigated in vivo and the expected 
outcome in human, which is an important message to many research fields.  
 
 
 
Figure Significance (ANOVA) 
1 rabbit vs mouse 2 µm p = 0.05; 
human vs rabbit 0.2 µm p = 0.3, 0.5 µm p = 0.018 
2 rabbit vs pig 0.2 µm p = 0.38, 0.5 µm p = 0.14, 5 µm p = 0.94; 
rabbit vs human 0.5 µm p = 0.21 
3 rabbit, pig vs human 5 µm p = 0.015, 2 µm p = 0.30, 0.5 µm p = 0.11; 
human vs pig 0.2 µm p = 0.033; 
human vs rabbit 0.2 µm p = 0.012 
4 rabbit vs human 2 µm p = 0.3134, 5 µm p = 0.16 
5 human (RBCs vs whole blood) 0.2 µm p = 0.48, 2 µm p = 0.067; 
mouse (RBC vs whole blood) 5 µm p = 0.76 
6 all p< 0.001 
8 human vs rabbit vs mouse 0.2 µm p = 0.084, 0.5 µm p = 0.14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4-2: p-value from balance one-way ANOVA, only  p ≥ 0.01 are shown 
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CHAPTER 5 
PLASMA PROTEINS IN DIFFERENT ANIMALS 
DIFFERENTIALLY AFFECT THE FUNCTIONALITY OF 
VASCULAR-TARGETED CARRIER  
Abstract 
 Animal in vivo assays in drug delivery research are preferentially compared with 
human in vitro study. However, these animals still have many differentiations relative to 
humans, which may obstruct the extrapolation to human physiological data such as shear 
rate, blood cell properties, and plasma protein composition. In this study, we investigate 
the potential role of different animal plasma proteins in dictating the adhesion efficiency 
of vascular targeted carriers (VTCs) of different material types to the vascular wall from 
blood flow in vitro. Specifically, PS, PLGA, silica and titanium particles were used as 
model VTCs in this study, and a monolayer of endothelial cells (ECs) at the bottom wall 
in a parallel flow channel served as a model vascular wall. The result showed that 
differences in plasma proteins composition in different species affect the capacity for VTCs 
to effectively bind to vascular wall in blood flow.  The negative adhesion of VTCs was 
most pronounced with PLGA in all animal blood and for all particle types in porcine blood. 
This study also show blood composition and blood properties play an importance role for 
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the binding efficiency of vascular-targeted carrier. Overall, we address the crucial factors 
of plasma protein-VTC interaction in different animal species with various VTC material 
types, which impact the validity of animal models for predicting VTCs outcome in human.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Content of this chapter is being prepared for publication.  
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5.1 Introduction 
Vascular-targeted carriers (VTCs) offers tremendous promise for use as an 
alternative for diagnosing and treating several human diseases due to the provided benefit 
of non-invasive and highly localized delivery to the disease area [1, 2]. To date¸ much 
research on the functionality of VTCs has mainly focused on novel strategies for targeting 
and drug release formulation [2] that allow for precise delivery and optimal drug release. 
However, these previous works assume successful VTC margination (localization and 
adhesion) to vascular wall in the blood flow. Recent publications have highlighted the 
importance of various physical and surface properties of VTCs, including size, shape and 
material characteristics, on the capacity to efficiently bind to the vascular wall in flow 
models ranging in complexity from simple in vitro buffer to in vitro blood flow assays [3-
8] to various animal models of human diseases [9-11]. In vivo assays are preferentially 
used in drug delivery research due to the (1) in ability of in vitro systems to fully recreate 
the complexity of the in vivo environment despite access to human tissues and cells ex vivo; 
and (2) the capacity to generate models of many human diseases in these animals at the 
cellular and molecular.  Several animal species are used in drug delivery research, 
including rodents, rabbits, pigs, dogs and monkeys [12-15]; however, differences in the 
physiology of these animals relative to humans, such as blood vessel size, blood flow 
magnitude, blood cell properties (aggregation, deformation, size and shape) and plasma 
protein composition, may prevent extrapolation of in vivo pre-clinical experimental results 
to clinic application in human [16] . In our recent research studies, we found that the human 
plasma protein has a negative effect on the vascular wall interaction of vascular-targeted 
carriers (VTCs) constructed from poly(lactic-co-glycolic-acid) (PLGA) polymer in a donor 
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(human) dependent manner [17]. However, little is known about the potential differential 
interaction of other animal plasma protein with VTCs in their bind to vascular wall 
endothelial cell, which is an essential component in understanding the translation of in vivo 
data to clinical relevance in human.  
To date, several publications have highlighted the importance of the plasma corona 
protein on targeted drug carriers, that differs for carriers of different material types[18], to 
their in vivo functionality; however, these studies have mainly concentrated on 
opsonization of particles and the impact recognition and clearance from bloodstream by 
phagocytic cells [19-21]. Only recently have a few works present evidence that particle 
corona protein characteristics can affect particle ligand-receptor interaction necessary for 
target recognition/specificity [22-24] . In addition, some studies claimed that persons 
express different biomolecules and form different corona in their blood [17, 25, 26], and 
the protein corona also can be applied for cancer diagnostic markers [27]. However, it is 
not yet known to what extent targeted particle interaction with plasma protein differ in 
different animal species and how such differences affect the carrier targeting outcome, 
especially in a complex environment such as blood flow.   
In this study, we investigate the differential vascular wall interaction of model 
VTCs in the flow blood from different animal in order to elucidate the impact of differential 
plasma protein corona for different material types via in vitro assays. Specifically, PS, 
PLGA, silica and titanium particles were used as VTCs model in this study. We 
characterize the adhesion of SleA conjugated particles to inflamed endothelial cells 
(overexpressing E-selectin) in laminar blood flow via a parallel plate chamber (PPFC) from 
different animal species (mouse, rabbit, porcine and human).  This study offers the first 
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evaluation of plasma protein in different animal species to determine how they affect VTCs 
under blood flow assays.    
5.2 Methods 
5.2.1. Particle fabrication  
Fabrication of 5 µm PLGA sphere, the oil-in-water solvent evaporation technique 
were applied as previously described [17, 28, 29]. Briefly, 50:50 PLGA polymer with acid 
(carboxyl) end group (Evoniks; Parsippany, NJ) was dissolved at 2 mg/mL in 20 ml of 
dichloromethane (DCM) (oil phase), and then the solution was filled in glass syringe and 
injected into 90 mL of polyvinyl alcohol (PVA)/poly(ethylene-alt-maleic anhydride) 
(PEMA) solutions (aqueous phase) under mixing batch. The emulsion was stirred for 2 hr 
in order to evaporate DCM. Subsequently, the emulsion was washed with ID water via 
differential centrifugation to diminish residual PVA on the particle surface. Finally, the 
particle solution was frozen and dried on a lyophilizer, and then stored dry at −20°C until 
use. The 500 nm PLGA spheres were obtained from Phosphorex, Inc. (Hopkinton, MA). 
These particles were also fabricated from acid (carboxyl)-terminated PLGA polymer with 
50:50 glycolic: lactic co-monomer ratio. The caboxylate-modified 500 nm silica spheres 
were purchased from Nanocomposix, Inc. (San Diego,CA). The 500 nm titanium spheres 
were procured from EPRUI Nanoparticles and Microspheres Co. Ltd. (Nanjing, China).    
5.2.2 Preparation of vascular-targeted particle 
Carboxylate-modified polystyrene spheres of 500 nm and 5.0 µm in size (Bangs 
Laboratories Inc., Fishers, IN) were covalently coupled with NeutrAvidin protein (Pierce 
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Biotech Inc., Rockford, IL) via carbodiimide (EDAC) chemistry as previously described 
[3-5]. Briefly, 5 mg/mL NeutrAvidin in 50 mM MES buffer (800 µL) was incubated with 
avidin-coated spheres (5.6x108 beads) on rotor for 15 min at room temperature. Then, 75 
mg/mL EDAC in 50 mM MES buffer (800 µL) was put in the avidin-particle mixture and 
adjusted pH to 9.0 via 1M NaOH. After 20 hrs incubation, the reaction was quenched by 
adding 100 mM glycine (concentration in mixture) and incubating for 30 mins. Avidin 
conjugated spheres were washed twice and resuspended in 50 mM PBS 1000 µL (50mM 
sodium dihydrogen phosphate and 50 mM sodium phosphate dibasic, pH 7.4). Particles 
were kept at 4°C until use.  
Avidin-coated spheres were conjugated with biotinylated multivalent sialyl Lewis 
A (sLe A; GlycoTech, Gaithersburg, MD) as previously described [3, 4]. Briefly, avidin-
coated sphere were incubated with sLe A in 50 mM PBS with 1% BSA on rotor for 45 mins 
at room temperature. The concentration of sLe A for each sphere types was varied to fix the 
same surface density for all sphere types. After conjugation, spheres were washed twice 
and resuspended with 1000 µL 50 mM PBS. Sphere surface ligand densities were 
quantified via BD FACsCalibur. A site density of approximate 1000 to 3000 sites/µm2 was 
used for in vitro experiments with sLe A. All procedures of avidin and sLeA conjugation 
were applied to PLGA, Silica and Titanium sphere as well.   
5.2.3 Preparation of human endothelial cells (ECs)  
The preparation of human umbilical vein endothelial cells (HUVECs) in this 
chapter is described in detail in chapter 3 via the well-known collagenase perfusion method 
[30, 31]. Confluent HUVEC monolayers were cultured on coverslips treated with gelatin 
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cross-linked with glutaraldehyde [32], and then activated with IL-1β at 1 ng/mL for a 4 hr 
period prior to use for experiments.  
5.2.4 Preparation of RBC-in-buffer and whole blood (WB) 
Human blood was collected from healthy adult donors via venipuncture as 
described in detail in chapter 3.  
To prepare human RBCs suspended in buffer, whole blood was spun down at 1000g 
for 30 min via centrifugation. RBCs was collected from the bottom layer, and plasma on 
the top layer was spun down again at 2250g for 30 min to diminish palettes and WBCs. 
RBCs layer was washed with PBS 3 three times via centrifugation at 1000 g for 30 min to 
minimize the excess anticoagulant and/or plasma constituents, then the RBC pellet was 
collected and resuspended in buffer (DPBS+ with 1% BSA (flow buffer)), viscous buffer 
(1.4% dextran in flow buffer), or plasma (spun plasma) to achieve a 40% hematocrit (% 
Hct), i.e. volume fraction of RBCs to plasma [4]. To prepare animal RBCs-in-buffer, 
isolated pig and rabbit RBCs were obtained commercially (Lampire Biological Lab, 
Pipersville, PA). For the murine RBC-in-buffer assays, mouse whole blood was collected 
from surplus mice, generously provided by the breeding colony of Unit of Laboratory 
Animal Medicine (ULAM) according to a protocol. Mouse procedures were approved by 
ULAM and University Committee on Use and Care of Animals (UCUCA) at the University 
of Michigan. Briefly, mouse blood was drawn from anaesthetized mice by a cardiac 
puncture into a syringe containing heparin as an anticoagulant. All the obtained animal 
whole bloods were prepared in the same way as human whole blood. For whole blood 
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experiments, mouse, pig and rabbit whole blood containing heparin and human whole 
blood containing ACD were stored at 4°C before use.  
5.2.5 Flow adhesion experimental set up 
A parallel plate flow chamber (PPFC) equipped with a silicon rubber gaskets 
forming the flow channel (GlycoTech, Gaithersburg, MD) were used for in vitro flow 
adhesion assays. Flow assays were constructed as described in a previous publications [4-
6]. Briefly, a single straight gasket was placed over an activated HUVEC monolayer 
cultured on a glass coverslip and vacuum-sealed to the flow deck to form the bottom 
adhesion substrate of the flow chamber assay. Vascular-targeted spheres were suspended 
in buffer or reconstituted blood at a fixed concentration of 5×105 beads/mL were introduced 
into the flow channel from an inlet reservoir via a programmable syringe pump (KD 
Scientific, Holliston, MA). Flow adhesion were observed on a Nikon TE 2000-S inverted 
microscope fitted with a digital camera (Photometrics CoolSNAP EZ with a Sony CCD 
sensor). Digital recording of experiments was via Metamorph analysis software. 
For laminar flow assays, the wall shear rate (WSR; γw), was computed using the 
approximation (chapter 3 and 4) 
𝛾𝑤(𝑠
−1) =
6𝑄
𝑤ℎ2
 
using the volumetric flow rate (Q) through the channel (mL/min), where h is the channel 
height (254 µm) and w is the channel width (1 cm). The wall shear stress (τw - dynes/cm2) 
can be calculated by multiplying the WSR by blood viscosity (μ), which is a function of 
temperature, Q, and blood hematocrit. 
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5.2.6 Data analysis 
Particle binding density (#/mm2) is obtained by manual count of the number of 
particles bound on the cell monolayer after 5 min of flow and dividing this number by the 
area of the field of view (20x magnification, A = 0.152 mm2) as previously described [5]. 
The data was collected at a constant position along the length of the chamber for all 
experiments. Each data point represents an average at least three experiments and includes 
at least 10 fields of view per experiment. Standard error bars were plotted unless otherwise 
stated. Differences in adhesion levels were analyzed using a student t test and one-way 
ANOVA with Tukey post-test. A value of p<0.01 was considered statistically significant 
[6].  
5.3 Result 
5.3.1 Effect of plasma protein on microsphere adhesion in buffer flows  
The purpose of this study is to evaluate the potential role of the plasma protein 
surface coating on the adhesion of targeted carriers to the vascular wall under flow 
condition.  Polystyrene (PS) and PLGA spheres in 5 µm in diameter were conjugated with 
SleA at the same site density (~1,000 sites/µm2). Both sphere types were incubated with 
flow buffer, human plasma, animal plasmas (rabbit, porcine and mouse) for 1 hr before 
running through the system. After 1 hr, spheres were washed before being introduced into 
the flow system with PBS buffer. We evaluate the binding efficiency of the sphere to an 
activated EC monolayer in low shear rate (200 s-1) laminar flow. On average (Figure 5-1), 
the adhesion of PS microspheres is significantly lower than PLGA  
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Figure 5-1. The adhesion efficiency of 5 µm spheres from buffer flow to an activated 
endothelial monolayer. (A) Adhesion of 5 µm polystyrene sphere to HUVEC monolayer 
under 200 s-1 laminar buffer flow for 5 mins, and (B) for 5 µm PLGA sphere. Particles were 
incubated in buffer (control) and pure plasmas (human, rabbit, porcine and mouse) for 1 hr 
before operating flow system. Particle concentration = 5e5 spheres/mL. * = p<0.05 relative 
to buffer control trial via one-way ANOVA. n ≥ 3.     
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microspheres in a simple flow buffer system, but not for porcine plasma soaked spheres 
(no significant difference between two sphere types). For the adhesion of PS sphere 
(Figure5-1A), all conditions have the same level of adhesion as buffer control. However, 
porcine plasma soaked spheres have 89% lower adhesion relative to the adhesion in buffer 
soaked spheres. Similarly, the EC adhesion of PLGA sphere opsonized in porcine plasma 
show radically 99% lower adhesion than their binding level in a simple buffer control as 
well (Figure5-1B).  Moreover, for human plasma opsonized PLGA spheres, adhesion level 
also displays 41% reduction from the simple buffer (similar result to previous study [17]), 
while rabbit and mouse plasma immersed spheres show a similar level as the buffer control. 
5.3.2 Evaluation of plasma protein and blood component effect to microsphere in 
blood flow 
 In this study, adhesions of 5 µm spheres both PS and PLGA were analyzed for 
several species to validate any variations in particle adhesion that may link to differences 
in the plasma protein and blood composition of each species. To determine the effect of 
plasma protein and blood component to particle adhesion under mimic physical conditions, 
RBCs were introduced into the flow system with viscous buffer (VB) (matching plasma 
viscosity) in order to increase particle-blood interactions compared to whole blood. Animal 
and human whole bloods were spun down to separate plasma layer (top part) and WBC 
(interface layer) out of the RBC layer (bottom part). The RBC layer was washed 3 times 
with PBS-/- to diminish the excess anticoagulant and plasma constituents. For all species, 
RBCs were adjusted to 40%hct in VB. Similar to the previous study, particles were 
opsonized in pure plasma for 1 hr before running the flow experiment with RBCs in VB in 
order to observe the effect of plasma protein on the particles. 
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Overall adhesion of polystyrene spheres shows an increase with RBC in VB 
compared to simple flow buffer (previous study), while an across the broad adhesion of 
PLGA sphere shows decrease from the previous buffer trial. These results are similar to 
our previous report [4, 17].     
 As shown in Figure 5-2A, for the adhesion level of PS spheres in human, the 
opsonized PS sphere had significant decrease binding compared to RBC in VB and whole 
blood (35% and 41% reduction, respectively). This result presents the negative plasma 
protein interference with the PS sphere binding correlated with plasma exposure time 
(particles were added into whole blood right before running flow assays). On the other 
hand, for the adhesion efficiency of PS spheres in the rabbit and mouse plasma the negative 
plasma protein effect on the spheres was absent, yet the binding of particles decreased in 
whole blood relative to RBC in VB in both rabbit and mouse (28% and 64% reduction, 
respectively). These results suggest that other blood components (WBCs and platelets) in 
rabbit and mouse bloods also have the potential role in particle adhesion. Interestingly, the 
adhesion level of PS particles in porcine declined in both plasma opsonized particle and 
whole blood relative to RBC in VB, 42% and 95% reduction, respectively. This 
observation suggests that both plasma protein and blood component have negative effect 
on particle binding in porcine blood.   
 Overall, adhesion of PLGA sphere (Figure 5-2B) had a strong negative effect on 
plasma protein and WBCs rather than the PS sphere. Specially, PLGA adhesion in human 
whole blood significantly dropped off from human RBC in VB, unlike the PS sphere.  
 
 
125 
 
 
 
  
 
 
 
 
  
 
 
 
Figure 5-2. Particle adhesion to activated HUVEC in laminar flow of blood at 200 s-1 for 
5 min. (A) Adhesion of 5 µm polystyrene sphere, and (B) Adhesion of 5 µm PLGA sphere. 
Both particle types were evaluated in human, rabbit, porcine and mouse blood. RBC+VB 
= washed RBCs in matched plasma viscous buffer, RBC+P+VB = 1 hr plasma opsonized 
particle in washed RBCs with matched plasma viscous buffer, and WB = whole blood.  
Particle concentration = 5e5 spheres/mL. * = p<0.05 relative to RBC+VB trial via one-way 
ANOVA. n ≥ 3.     
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Moreover, the plasma protein interference with binding was slightly present in plasma 
opsonized PLGA microparticles in rabbit and mouse. These results suggest that extent of 
the negative adhesion effect of plasma protein occurred on PLGA sphere.     
To further determine whether the protein absorption on PLGA particle or blood 
constituent cause more differential adhesion to activated ECs, especially in porcine and 
mouse blood flow,  washed RBCs in pure plasma (cell removed plasma) assay was included 
in the extended experiment. Figure 5-3A shows a noticeable decrease particle binding in 
porcine RBCs in plasma and porcine whole blood relative to RBCs in VB and plasma 
incubated particles (RBC+P+VB). This result shows that the plasma protein corona effect 
on adhesion of PLGA particle overcomes the effect of other blood components (WBCs and 
platelet) in porcine blood flow. In contrast to mouse blood (Figure 5-3B), there is no 
significant difference between adhesions in both mouse plasma opsonized PLGA particle 
in VB and mouse RBC in plasma, which  moderately decrease from mouse RBC in VB 
(20% and 31% reduction, respectively). However, the adhesion of PLGA sphere is absent 
in mouse whole blood flow. It exhibits that mouse blood constituent has a potential role in 
PLGA particle binding rather than mouse plasma protein corona effect.   
5.3.3 Evaluation on plasma protein effect to nanoparticles in various material types 
under blood flow. 
 According to the previous experiment, the effect of plasma protein absorption on 
PLGA microparticle adhesion was pronounced in porcine, human and mouse, respectively. 
To further study whether this observed plasma protein effect distinctly appears in PLGA 
microparticles or expands to nanoparticles or other material types too,  
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Figure 5-3. Adhesion of PLGA microparticle to activated HUVEC in laminar flow of 
blood at 200 s-1 for 5 min. (A) Porcine blood flow, and (B) Mouse blood flow. RBC+VB 
= washed RBCs in matched plasma viscous buffer, RBC+P+VB = 1 hr plasma opsonized 
particle in washed RBCs with matched plasma viscous buffer, RBC+plasma = washed 
RBCs in pure plasma (cells removed plasma), and WB = whole blood.  Particle 
concentration = 5e5 spheres/mL. * = p<0.05 relative to RBC+VB trial via one-way 
ANOVA. n ≥ 3.     
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we evaluated the adhesion of PS, PLGA, silica and titanium nanoparticles (500 nm) to 
activated ECs from porcine and mouse laminar blood flow similar to the previous 
experiment. 
Similar to previous results, the extent of the negative adhesion effect of porcine 
plasma protein is more prominent in all material types of nanoparticles compared to mouse 
plasma (Figure 5-4A). Even though some level adhesion of nanoparticles were observed in 
silica and titanium nanosphere with porcine RBC in plasma and whole blood trial, these 
adhesion levels still do not fully recover the adhesion level under buffer conditions. 
Additionally, the adhesions of 500 nm silica and titanium particle are significant higher 
than PS and PLGA nanosphere in RBC in VB. This result shows the positive adhesion 
effect of high density material similar to our previous report.   
 The adhesion levels of nanospheres in mouse RBC with plasma flow are highest in 
all material types, and lowest in mouse whole blood flow(Figure 5-4B), which is in contrast 
to porcine blood flow. This result interestingly reveals that the protein plasma corona effect 
was absent in adhesion of nanospheres with mouse blood flow; however, mouse blood 
component still negatively affect the nanoparticle binding which is shown in whole blood 
results. Moreover, overall adhesions of nanospheres with mouse whole blood flow are 
higher than adhesion of microparticles (5 µm PS and PLGA spheres), which suggests that 
nanoparticles are less detached by mouse WBCs and platelets than micro sized particles. 
In addition, the responsive adhesion of particle to viscosity of buffer is more pronounced 
in nanoparticles than in microparticles, particularly in mouse blood (small RBC) (Figure 
5-5). Therefore, adhesions of nanoparticles in mouse RBC in plasma are significant higher 
than in VB for all material types (Figure 5-4B).   
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Figure 5-4. Adhesion of nanoparticles (500 nm) to activated HUVEC in laminar flow of 
blood at 200 s-1 for 5 min. There are 4 material types in this set of experiment; polystyrene, 
PLGA, silica and titanium. (A) Porcine blood flow, and (B) Mouse blood flow. RBC+VB 
= washed RBCs in matched plasma viscous buffer, RBC+plasma = washed RBCs in pure 
plasma (cells removed plasma), and WB = whole blood.  Particle concentration = 5e5 
spheres/ml. * = p<0.05 relative to RBC+VB trial via one-way ANOAVA. n ≥ 3.     
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Figure 5-5. Adhesion of polystyrene nanoparticles (500 nm) to activated HUVEC in 
laminar flow of washed mouse RBCs at 200 s-1 for 5 min with different viscosity of 
buffer (PBS buffer, 1.4%(w/v) Drextran in PBS buffer and 2.0% (w/v)Drextran in PBS 
buffer).  
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5.4 Discussion  
In biological fluids (plasma or otherwise), a range of proteins associate with VTCs 
to form a “protein corona” that defines the biological character of the particle. The protein 
corona formation depends on the geometric and physicochemical properties of the targeted 
drug carrier, such as size, charge, material type, curvature and targeting moieties on their 
surfaces [21, 33, 34]. Many recent publications have focused on identification of corona 
protein composition on plasma opsonized particles and the downstream effect of in vivo 
circulation time and blood clearance; however, few studies have shown that corona protein 
interferes with the ligand-receptor interaction on particles [22-24]. In particular, there is 
limited understand on explored how the plasma protein type and composition in different 
animal species affects particle adhesion in blood flow. In this study, we investigated the 
role of plasma protein in different animal species on micro and nano particles in various 
material types under laminar blood flow. The data in Figure 5-1 illustrates that overall 
adhesions of PS microsphere are significantly lower than adhesion of PLGA microsphere 
in buffer flow. This result is linked to material density, which is linked when higher density 
material has more force to break through stream line in flow and marginate to ECs. 
Therefore, PLGA (1.34 g/cm3) has higher density than PS (1.05 g/cm3), resulting in higher 
binding in PLGA particles. Also, the adhesion of porcine plasma opsonized particles in 
both PLGA and PS microparticle is radically low compared to other species. We conclude 
that porcine plasma has a strongly negative protein effect on the adhesion of microparticles, 
and it may form different corona protein compositions from other species on the surface of 
the particles as well. Additionally, human plasma soaked PLGA microparticle exhibit 
reduced vascular wall binding relative to buffer control, which exhibits the critical negative 
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plasma proteins specific to material type (PLGA particle). This effect is not observed for 
PS microspheres, which is supported by our previous study as well [17]. Our results are 
similar to other reports, which claim that different material types affect the different 
adsorbed corona proteins on particles with the same size and surface charge [17, 18].   
In a further study, we introduced blood cell and matched plasma viscous buffer with 
particles into flow assays. The particle-blood cell interactions have previously been 
reported between microspheres and RBCs and WBCs [6]. The adhesion of 5 µm PS 
particles drastically increase in laminar flow when adding RBCs into the flow which is also 
shown in Figure 5-2A for all PS microparticles binding. The data (Figure 5-2) agrees with 
the buffer flow study that showed porcine plasma has a strongly negative effect on the 
adhesion of particles. Moreover, the significant decrease of both PS and PLGA 
microspheres in human plasma soak particles comparative to whole blood and viscous 
buffer implies that the negative protein depends on plasma exposure time, which also was 
revealed in the previous study [17]. The negative plasma protein effect to particle binding 
is still more pronounced for the PLGA microparticle (both human and porcine) compared 
to PS in general. Interestingly, the negative protein effect is completely absent in rabbit 
and mouse plasma in PS microparticle binding and has a slight effect on PLGA 
microparticle binding; however, all these adhesions are significantly lower in whole blood 
flow relative to RBC in VB both rabbit and mouse. This result suggests that there are other 
components in blood beyond RBCs and plasma proteins affecting microparticle binding. 
WBCs and platelets might play a potential role in particle margination under blood flow. 
Chareonphol et al. reported that leukocytes can cause the collision-induce removal of 
bound microsphere or the enhancement of microsphere binding depending on share rate, 
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blood flow pattern and %hct [6]. In an extended study, washed RBCs in pure plasma was 
included in the experiment. Our results show that the effect of plasma protein is dominant 
for the negative adhesion of PLGA microparticles in porcine blood, but the reduced 
adhesion of particle in mouse whole blood is mostly due to the impact of other blood cell 
components (WBCs and platelets).  
Some studies have found that for copolymer, gold, or other metal nanoparticles with 
various diameters, the amount of absorbed protein on surface varied with size and surface 
curvature, and the qualitative changes of protein also depend on the size of the particles in 
the obtained corona protein[17, 18, 21]. The potential explanation is a larger ratio of surface 
to volume which allows more protein to bind to smaller particles than to particles of larger 
sizes, and total surface area differences [17, 21]. Moreover, some investigators also pointed 
out that nanoparticles with different material and different sizes are associated with 
different corona proteins [35]. Therefore, we included nanoparticles (500 µm sphere) of 
various materials (PS, PLGA, silica and titanium) in our expanded study.  The strong 
negative adhesion effect of porcine plasma protein to particle is still observed in all material 
types of nanoparticles, but silica and titanium nanospheres slightly recover from this effect. 
The results suggest that porcine plasma may consist of a variety and a larger amount of 
protein than other species, which can be associated with biomaterial forming broad corona 
protein layers and also interfere with targeting moieties on the material surface. On the 
other hand, the negative plasma protein effect to nanoparticle adhesion absent in mouse 
blood relative to porcine blood. The distinction of negative plasma protein effect on particle 
adhesion is less pronounced for nanospheres evaluated in mouse blood likely because 
adhesion can be overcome by an induced effect of a blood cell-particle interaction for 
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nanoparticles. We previously reported that the adhesions of 500 nm particles show a 
significant increase in mouse blood which has small RBCs relative to other species blood 
[chapter 4]. Therefore, herein the adhesion of nanoparticles in mouse whole blood also 
shows an increase compared to adhesion of microparticles similar to the previous study 
[chapter 4]. However, the significant difference in the adhesion of nanoparticles in mouse 
whole blood and mouse RBCs in plasma assays suggests that the mouse blood component 
still has a negative effect compared to nanoparticle adhesion which is not shown in human 
whole blood [6]. In mouse blood composition, the main component of the mouse’s WBCs 
is lymphocytes which is smaller than mouse RBCs, while humans have more neutrophils 
which are twice as large as human RBCs. As mentioned above, human WBCs interfere 
with microparticle binding [6], so the smaller size of WBCs may interfere with particle 
adhesion as well.  Additionally, the adhesion of nanoparticles in mouse RBCs in VB 
(matched with human plasma) is lower than in mouse RBCs in plasma and data from Figure 
5-5 would suggest that the viscosity of plasma is another factor which dictates nanoparticle 
adhesion; however this requires further study in order to be verified.   
In conclusion, our study addresses many potential factors that concern the adhesion 
of micro and nanoparticles in different species which can be translated to human data. First, 
the study shows that the plasma proteins in different species affect the different level of 
particle binding, especially in porcine which shows strong negative effect to particle 
adhesion. This crucial factor is a matter of concern for further in vivo studies in animal 
model or pre-clinical trials for drug delivery. Second, this study shows blood composition 
(RBCs and WBCs) and blood properties (size) play an importance role in the binding 
efficiency of vascular-targeted carriers. Third, using different material types of particles 
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causes in differences in corona protein formation which interfere with particle adhesion. 
Lastly, although it’s not clear what role the viscosity of plasma on nanoparticle binding, 
our study shows that it has an effect on the adhesion of nanoparticles with small RBCs as 
mouse blood. Overall, by addressing the crucial factors of plasma protein- particle 
interaction in different animal species with various material types of particles, we reveal 
potential deviation of results in animal models and the predictable outcome in humans. 
This is an important for many research fields, particularly, drug delivery and diagnostics 
in cardiovascular. 
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CHAPTER 6 
CONCLUSIONS AND FUTURE WORKS 
6.1 Conclusions and Significant Contributions 
 Drug delivery systems (DDS) remain one of the most distinguished aspect in the 
field of biomedical and pharmaceutical engineering, particularly DDS developed for the 
targeting of therapeutics or imaging moieties to the vascular wall in human diseases.  
Vascular-targeted DDS are advantageous due to the benefits of decreased in side effect 
associated with the localized delivery, the ability to sustain drug release and the increase 
in patient compliance. Because these advantages improve the traditional therapies, many 
variants of vascular targeting carriers have been proposed for use as alternative treatment 
for cancer as well as for pulmonary and cardiovascular diseases. In order to design an 
efficient drug carrier for targeted drug delivery, there are three crucial criteria that must be 
considered: targeting properties, physical properties, chemical properties and 
hemodynamics properties.  
6.1.1 Targeting Properties 
 To achieve the targeting specificity, the surface of drug carriers is typically altered 
by decorating with ligand molecules with affinity to proteins and other molecules 
specifically expressed at the target. In this study, we focus on sialyl-lewis A (Sle A) 
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(Chapter 3, 4 and 5), a carbohydrate ligand specific affinity to selectin, as the targeting 
ligand on vascular-targeted drug carrier with specificity for the E-selectin protein expressed 
on inflamed endothelial cells. SleA was use as the model ligand because SleA –coated 
particles are effectively captured under high-shear flow similar to leukocyte binding to the 
vessel wall. However, these particles have weak adhesion force which can detach under 
high shear rate or by WBCs rolling motion. Therefore, the particles in chapter 2 were 
decorated with dual-targeted ligands (SleA and anti-VCAM) at the optimal ratio because 
antibody molecules (anti-VCAM) help particles to resist the high shear force and still 
adhere under in vivo condition.   
6.1.2 Physical Properties 
 Beyond specifically binding to the targeted sites, the VTCs must also be able to 
marginate (localize and adhere) to vessel wall through the bulk blood flow. The physical 
properties of drug carrier are important factors to localize VTCs to the vascular wall in 
blood flow. In chapter 2, we concluded that particle shape, particle size, and targeting 
moiety all play a role in prescribing the adhesion and biodistribution profile in a mouse 
model of atherosclerosis. Specifically, we found that the ellipsoidal microparticles of 
aspect ratio (AR4) with volume equivalent to 2 μm diameter spheres are more efficient on 
the targeting inflamed endothelium in the aorta of atherosclerotic mice than microspheres 
of equal volume and nanoparticles, especially in plaque areas. Further, these micro-rods, 
when untargeted, displayed a similar level of minimal mechanical entrapment in the lung 
capillaries compared to their spherical particles. Thus, the ellipsoidal geometry at the 
appropriate aspect ratio may be an advantageous shape to use when designing drug carriers 
for targeting the aorta, in order to deliver the highest possible payload of therapeutics or 
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diagnostics in atherosclerosis. However, more targeted micro-rods than microspheres and 
nanoparticles are retained in the lungs at higher levels compared to their untargeted 
particles due to molecular interaction with inflammatory molecules in the pulmonary 
vasculature of atherosclerotic mice.  
1.6.3 Chemical Properties 
In addition to the geometry of particles, the material type is also a crucial factor in 
particle binding efficiency due to differences in density and physicochemistry of particle. 
The discussion in chapter 5 confirms that the plasma protein-particle interaction in different 
material types of particles causes the differences in corona protein formation on the particle 
surface which interferes with particle adhesion as well. As the results show in chapter 5, 
human plasma soaked PLGA microparticle reduced binding relative to buffer control, 
which exhibits the critical negative plasma proteins specific to material type (PLGA 
particle), and this effect is not observed for PS microspheres. These discoveries are 
beneficial to VTCs design and imaging techniques because the provided optimal physical 
properties (size, shape and material) can be utilized to effectively deliver medication.    
6.1.4 Hemodynamic Properties 
 Hemodynamics, the movement of blood cells in the circulatory system, is enforced 
by flow dynamics that can be changed by the characteristic of blood vessel and blood 
properties. Chapter 3 reveals that the adhesion efficiency of particles is dependent on the 
vessel size, WSR and blood hematocrit because these parameters effect “cell free layer” 
formation and particle-RBC interaction.  The cell free layer typically decreases with 
decreasing vessel diameter at a fixed hematocrit. Therefore, a smaller cell free layer is 
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anticipated in the 28 µm channel height relative to the 43 µm channel height, which likely 
results in a higher local concentration of spheres at a closer proximity to the wall. A higher 
concentration of spheres at the wall would in turn lead to higher adhesion efficiency. The 
results of chapter 3 also show that the shear rates (WSR) also affect particle binding, 
especially given that the adhesion efficiency of 5 µm particles significantly decreased for 
all WSR increases in both channels. Because 5 µm particles exist in a reaction-limited 
regime (RLR), in which a high slip velocity is exhibited by these spheres and the higher 
disruptive force acting on them inhibit their adhesion at high WSRs, hence the decrease in 
adhesion density is observed for the 5 µm particle as the channel WSR increases. Lastly, 
the results in chapter 4 also show that flow pattern also plays an importance role in the 
adhesion of particles. Specifically, pulsatile flow tends to decrease microparticle binding, 
but recirculating flow enhances the adhesion of microparticles, particularly the 
reattachment point which presents low shear rate (favored for microparticles). 
Understanding the role of hemodynamics on prescribing the VTCs binding efficiency is 
valuable since these discoveries allow for flexibility in VTCs design for various conditions 
of diseases and blood vessels.     
Furthermore, rheology is one of the crucial factors for efficacy of particle adhesion, 
including %Hct, RBC dimension, and plasma protein. In chapter 3, the studies shows that 
%Hct is an important factor that affects flow resistance in microvessels and the formation 
of the cell free layer. As shown in chapter 3, the adhesion density of 2 µm particle 
significantly increased as the blood Hct increased from 10% to 50% in the 43 µm channel, 
but the adhesion of 5 µm particle dropped when increased to 50%hct. These result is due 
to the shrinking of the cell free layer in response to the enlargement of the RBC core and 
145 
 
hence a higher packing of small particles closer to the endothelial wall.  However, for larger 
particles there is increased in collision with RBCs with the larger RBC core and this 
disruptive force lead to detachment of large particles. Additionally, this study also sheds 
light on the relevance of the relative size of the particle to the RBC dimension in different 
species on particle binding, as discussed in chapter 4. According to the results, the optimal 
diameter of particles can be predicted with a mathematic model for each species along with 
blood flow patterns. Last but not least, the studies in chapter 5 conclude that the plasma 
proteins in different species affect the different levels of particle binding, especially in 
porcine which shows strong negative effects on particle adhesion. Overall, these studies 
reveal potential deviations of results observed in animal models and the predictability of 
the outcome in humans. This is important for drug delivery and diagnostics in 
cardiovascular research fields. 
6.1.5 Implication of hemorheology in clinical aspect 
Our studies and results particularly concentrate on application for atherosclerosis, 
however; this studies also can be applied into several physiological and pathophysiological 
conditions in human.  
As discussed earlier, particle adhesion efficiency is strongly dependent on 
hemodynamic and hemorheology. In physiological condition, whole blood viscosity is 
reflected by hematocrit level.  Hematocrit in a given individual may not remain constant 
but may change significantly as a part of physiological and pathophysiological conditions. 
An acute rise in hematocrit might be the result of a relative increase of RBCs mass in 
circulatory system caused by fluid loss by various means such as gastrointestinal and 
urinary tract, and by constriction of the volume of the circulatory system. These conditions 
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also affect the protein concentration of plasma and increasing plasma viscosity too. In 
addition, high hematocrit can also be caused by erythrocytosis, which is the production of 
more red blood cells by bone marrow, polycythemia vera and Cor pulmonale (COPD, 
chornic sleep apnea, pulmomary embolism). According to the correlation of these physical 
conditions and symptoms with our previous studies in chapter 3, the margination of 
nanoparticle may be optimized in these conditions.  
 Additionally, our study also show the relevance of the relative size of the particle 
to the RBC dimension, as discussed in chapter 4. The physical properties of RBC such as 
dimension and deformability have significant effect on flow resistance in vascular system 
and hence also impact the adhesion of VTCs. Several diseases that show unusual property 
of RBCs such as macrocytic anemia which RBCs have insufficient concentration of 
hemoglobin resulting larger than their normal volume which have more interaction with 
larger particle during blood flow. On the other hand, microcytic anaemia caused by iron 
deficiency anemia and thalassemia show smaller RBCs than normal dimension which may 
enhance nanoparticle adhesion as deliberated in chapter 4. 
 In addition to the hematocrit and dimension of RBCs, their rheological properties 
are also important determinants of blood fluidity. The unique shape and structure of RBCs 
provide special mechanical properties, which they can changes their shape responding to 
dynamic force known as RBC deformability resulting the formation of RBC core layer in 
vessel during blood circulation. This study demonstrated that most of nanoparticle tend to 
be entrapped into RBC core layer, which limits the particle margination to vessel wall as 
discussed in chapter 3. However, several diseases such as sickle cell anemia could have 
abnormal, rigid, inelastic and sickle-like shape RBCs effecting deformability in blood flow 
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and also RBCs core layer which may decrease the entrapment of nanoparticle between 
RBC and then enhance margination of nanoparticle to the vessel wall. 
Lastly, according to chapter 5, we found that plasma viscosity also play important 
role in particle adhesion due to shear force on vessel wall during blood flow. In general, 
the level of plasma viscosity is good indicator of disease process and pathophysiological 
condition associated with acute phase reaction related to the protein content of plasma. 
Plasma viscosity can increase up to 5-6 cP (normal plasma viscosity is 1.10-1.35 cP) in 
patients with abnormal protein levels known as paraproteinemais which presence of 
excessive amounts of papraprotein or single monoclonal gammaglobulin in the blood. As 
discussed in chapter 5, immunoglobulins are one class of protein prominently present in 
the protein corona on the surface of particle interfere with particle adhesion.     
 Overall, these studies reveal potential correlation between hemodynamics 
describing particle adhesion extended into clinical side by providing the cases of 
physiological and pathophysiological conditions in human. This is essential for designing 
drug delivery in other hematological conditions beside atherosclerosis. 
 
 
 
 
 
 
 
 
148 
 
6.2 Future Works 
Even though this dissertation evaluates the role of particle geometry (size and 
shape), hemodynamics, and hemorheology, which are significant strategies necessary in 
designing the optimal vascular-targeted carriers (VTCs) used in imaging and therapeutic 
delivery in cardiovascular diseases, the investigation in this field could be further 
developed and extended in the following directions. 
 (1) Extend development of the in vitro flow adhesion assay to acheive the 
physiological conditions as encountered in human.  
(1.1) Use the cylinder flow system. Since most of this study uses rectangular 
channel as in vitro flow assay, which does not represent the real vessel geometry, thus, the 
cylinder flow system would be more suitable to be use as the assay. The particle binding 
trend in the cylinder tube could be different due to various factors including the velocity 
profile that occurred in different coordinating systems. However, this system still has 
limitations in channel fabrication and culture cells at the system wall.    
(1.2) Observe the adhesion of VTC at smaller channel height (10-15 µm) with 
bifurcation or capillary network mimicking flow channel, which are the characteristics of 
disease sites such as  atherosclerotic plaque area in arterioles and vascular network in 
cancer tissue. These studies would determine the trend of particle binding and possibly 
suggest the optimal VTC geometry used for targeting specifically to lesion areas. 
 (2.) Investigate the potential role of other materials on particle behavior in blood 
flow. Though the serveral material types (PS, PLGA, silica and titanium), VTCs used in 
chapter 5, are commonly employed for in vitro assays only PLGA is biodegradable 
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material. Therefore, other material such as polycaprolactone (PCL), hydrogel or biological 
materials would be preferable for in vivo research due to their biodegradability and 
biocompatibility. Due to the different properties of these materials such as density, surface 
characteristics and physicochemistry, the behavior in blood flow and the interaction with 
blood cells of these particles could be different and thus may effect their binding efficiency 
as well. 
(3) Further investigate the potential role of WBCs in the different particle binding 
density in difference animal species, previously observed in Chapter 5. Specifically, the 
effect of WBC size, WBC concentration and specific WBC type in various animals on 
particle binding may need to be revisited and carefully examined. 
(4) Identify the specific plasma protein interfering with particle binding in blood 
flow. As shown in chapter 5, some species such as porcine and bovine have a strongly 
negative protein plasma effect on the adhesion of particles; otherwise some species such 
as rabbit and mouse show a slight effect on plasma protein. However, we have not known 
which specific proteins in each animal plasma have strong interactions with targeting 
molecule and material surface, and then reduce binding efficiency of the particles. Thus, 
characterization of plasma protein on particles is crucial for enhancing affinity and sustain 
the particle in the circulation system.  
(5) Include blood that is similar to the human physiology in the study such as 
orangutan or chimpanzee, due to the similarity in blood geometry and plasma protein to 
humans. This would result in a more accurate prediction as the ape blood data would be 
complied in the results in chapter 4 and 5 and could be add to mathematical model.          
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(6) Determine the role of particle physical properties (e.g. size, shape and surface 
charge) in dictating the internalization of VTCs in the endothelial cells and macrophage 
under blood flow condition.  
Even though there is much room for further study, the studies presented here as a 
preliminary provide several crucial factors for designing drug delivery system and 
enhancing drug efficiency. They are essential for drug delivery and diagnostics in further 
cardiovascular research fields. 
 
 
